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I. LIST OF ABBREVIATIONS 
 
AIP autoimmune pancreatitis 
ALAT alanine transaminase 
ALP alkaline phosphatase 
AP acute pancreatitis 
APA American Pancreatic Association 
APP acute pediatric pancreatitis 
ARP acute recurrent pancreatitis 
ASAT aspartate transaminase 
ATP adenosine triphosphate 
BUN blood urea nitrogen 
CFTR cystic fibrosis transmembrane conductance regulator 
CI confidence interval 
CP chronic pancreatitis 
CRP C-reactive protein 
CT computed tomography 
DM diabetes mellitus 
EBM evidence-based medicine 
EEN early enteral nutrition 
FAEEs fatty acid ethyl esters 
γGT gamma-glutamyltransferase 
HPSG Hungarian Pancreatic Study Group 
HTG hypertriglyceridemia 
HTG-AP hypertriglyceridemia-induced acute pancreatitis 
IAP International Association of Pancreatology 
ICMJE International Committee of Medical Journal Editors 
ICU intensive care unit 
IVF intravenous fluid 
LDH lactate dehydrogenase 
LOH length of hospitalization  
Max CRP maximum C-reactive protein 
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Max WBC maximum white blood cell count 
MOF multi organ failure 
NPO nil per os 
PC pancreatic cancer 
PICO participants, intervention, comparison and outcomes 
PINEAPPLE Pain IN the EArly phase of Pediatric Pancreatitis 
PRISMA-P 
preferred reporting items for systematic review and meta-analysis 
protocol 
RBC red blood cell count 
ROC receiver operating characteristic 
SAP severe acute pancreatitis 
SIRS systemic inflammatory response syndrome 
sPEM serum pancreatic enzyme measurement 
TG  triglyceride 
TPN total parenteral nutrition 
US ultrasonography 
WBC white blood cell count 
WHO World Health Organization 
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II. GENERAL INTRODUCTION 
 
II.1. Challenges in acute pancreatitis 
Acute pancreatitis (AP) is one of the most common reasons for gastrointestinal 
hospitalizations in adults (1, 2). AP has an annual incidence of 13-45 per 100,000 persons and 
is increasing worldwide as a result of better awareness of the disease and obesity-related 
gallstone formation and hypertriglyceridemia (HTG) (3, 4). AP represents a remarkable disease 
burden for healthcare systems and patients’ quality of life (5). This burden is further increased 
by the development of a severe disease course which is accompanied by increased length of 
hospitalization (LOH), elevated rate of complications, intensive care unit (ICU) stay, the need 
for invasive interventions, and mortality (5).  
According to the revised Atlanta classification, the severity of AP is categorized as 
mild, moderately severe, and severe (6). Severe acute pancreatitis (SAP) develops in 15-20% 
of AP cases (1, 6); however, better understanding of the underlying mechanism may provide 
possibilities for decreasing severity. Although the pathomechanism of AP is still unclear, the 
most common etiological factors such as bile acids (7-10), fatty acids generated from TG, and 
non-oxidative ethanol metabolites (fatty acid ethyl esters, FAEEs) (11-16) were shown to cause 
mitochondrial damage with resultant adenosine triphosphate (ATP) and energy depletion in the 
exocrine pancreas. In addition, HTG contributes to systemic pro-inflammation and local 
hypoxia-induced acidosis caused by hyperviscosity (17, 18). According to these data, HTG was 
shown to increase the risk of the development of SAP (19-26) and aggravate the severity of AP 
compared to alcoholic and biliary etiologies (27, 28). In contrast, early enteral nutrition (EEN) 
as early ATP restoration has been shown to be beneficial in AP compared with nil per os (NPO) 
therapy and total parenteral nutrition (TPN) regardless of the severity of AP (29-34). 
Accordingly, initial and appropriate lipid-lowering therapy may be beneficial in the case of 
hypertriglyceridemia-induced acute pancreatitis (HTG-AP), whereas energy restoration via 
enteral nutrition may play a key part of the therapy in all cases of AP. However, detailed 
analysis and evidence-based therapy for HTG-AP is missing, and despite the fact that the 
clinical characteristics of AP differ by age, nutritional guidelines for childhood-onset AP are 
limited and adopted from the adult protocols (35-41). 
Not only therapeutic, but also diagnostic pediatric guidelines for AP are adopted from 
adult protocols (37, 38). Some of these guidelines are based on the consensus of expert pediatric 
pancreatologists, but not on evidence-based pediatric data (42, 43). The recently published APP 
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guideline has low evidence as well (37). It is not surprising that the overall incidence of acute 
pediatric pancreatitis (APP) is lower compared to the adult population (1 per 100,000 persons 
or even less versus 13-45 per 100,000); however, two major studies have proven that the real 
incidence of APP (3.6–13.2 per 100,000) is much higher than we previously thought (3, 44-
46). The reason is probably multifactorial, but it has been published by Morinville et al., that 
diagnostic workup influences the incidence of the disease (44). Their data showed that 
increased pancreatic enzyme testing could account for 94% of the change in all AP admissions 
in childhood, suggesting that APP is an underdiagnosed disease.  
In contrast with the current diagnostic practice, there is significant importance in 
recognizing and diagnosing AP in childhood. Acute recurrent pancreatitis (ARP) develops in 
10-35% of children following an initial AP (38, 47, 48), and idiopathic ARP is likely to be a 
transition phase between AP and chronic pancreatitis (CP) (49, 50) with 1-3.79 years of median 
time (51, 52). However, based on a multicenter study, 16% of the pediatric CP patients had no 
documented prior episode of ARP (51). ARP and CP are of great importance because both are 
associated with a notable disease burden by pain, exocrine and endocrine dysfunction, frequent 
ER visits, hospitalizations, and school absenteeism (51). The most common risk factors of CP 
are alcohol and smoking in adults; however these are uncommon in children (53). Pediatric 
ARP and CP are frequently associated with pancreatobiliary obstructions in ~30% and genetic 
abnormalities in up to 73% (51, 54, 55). Genetic involvement was shown to carry the fastest 
rate of progression from AP to CP (55). These data highlight the necessity of an appropriate 
and evidence-based diagnostic guideline for childhood-onset AP.  
 
II.2. Motivation for my scientific work 
As a pediatric resident I recognized the importance of evidence-based clinical practice 
compared to decisions based on the experiences of individual physicians. First, we aimed to 
estimate the real incidence of APP and improve the diagnostic workup of childhood onset AP 
by establishing an international, multicenter observational clinical trial called PINEAPPLE 
(Pain IN the EArly phase of Pediatric Pancreatitis) (56). Furthermore, we reviewed the 
literature to analyze the effect of EEN versus NPO therapy on the outcome of APP and 
aggregate the information to increase the statistical power of nutritional AP guidelines in 
childhood compared to individual studies (57). Finally, we performed a cohort analysis of 716 
adult AP cases to investigate the dose-dependent effect of HTG on AP and provide detailed 
data for further prospective randomized clinical trials (58, 59).  
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III. DOSE-DEPENDENT EFFECT OF HYPERTRIGLYCERIDEMIA ON ACUTE 
PANCREATITIS 
 
III.1. Introduction 
HTG affects 10–30% of the general adult population (60, 61). Classifying HTG is 
complex; both genetic (primary) and environmental (secondary) factors can lead to an elevated 
triglyceride (TG) level. In rare cases (2%), primary severe HTG (TG≥10 mmol/l) may arise as 
a result of autosomal recessive, monogenic familial chylomicronemia syndrome (FCS, former 
Type I). However, a majority of severe HTG cases are multifactorial and have polygenic 
(mixed HTG, former Type V) determinants with additional secondary factors. Mild-to-
moderate HTG cases (2–9.9 mmol/l TG) are similarly polygenic with complex genetic 
susceptibility (former Type IV, Type IIB and Type III) (3, 61, 62). Regarding environmental 
factors, alcohol, positive-energy balanced diet, obesity, uncontrolled diabetes mellitus (DM), 
renal diseases, pregnancy, hypothyroidism, and medications (e.g., estrogen, retinoids, 
thiazides, and β-blockers) were shown to be responsible for a raised TG level, usually with the 
interaction of genetic susceptibility (18, 63). 
HTG is the third most common cause of AP, and is responsible for up to 15% of AP 
cases (26, 64, 65). According to the definition, the majority of experts agree that AP related to 
TG above 5.6 mmol/l should be considered as suspected HTG-AP, and AP associated with TG 
over 11.3 mmol/l is confirmed as HTG-AP (24, 62). Importantly, the occurrence of AP 
increases with the increase in TG level. There is a 5% possibility of developing AP if TG 
exceeds 11.3 mmol/l, and this rises to 10–20% if TG elevates to over 22.6 mmol/l (62). HTG-
AP is of great importance for several reasons: i) it has shown a rising incidence worldwide as 
a result of increasing obesity-related dyslipidemia (4, 25); ii) it raises the risk of severe AP and 
related complications (20, 24-26, 66-68); and iii) there is no evidence-based therapy for it (35, 
36, 39, 40).  
 
III.2. Aims 
We aimed to perform a cohort analysis for investigating the dose-dependent effect of 
HTG on AP and providing data for further prospective randomized clinical trials. 
 
III.3. Methods 
AP patients (n=1435) over 18 years old were enrolled in the prospectively collected 
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international, multicenter AP registry operated by the Hungarian Pancreatic Study Group 
(HPSG) between 2012 and 2017. Post-hoc cohort analysis was performed on 716 AP cases 
who underwent TG measurement within 72 hours of admission. AP was diagnosed based on 
International Association of Pancreatology/American Pancreatic Association (IAP/APA) and 
HPSG evidence-based guidelines (35, 36). Participating countries are shown in Fig. 1. 
 
Fig. 1. Participating countries. Distribution of participating countries and number of enrolled acute pancreatitis 
cases (n=1435). 
 
The threshold of the normal TG value was determined at 1.7 mmol/l (63). Six groups 
were established based on the Endocrine Society Clinical Practice Guideline and previously 
published clinical data related to HTG-AP (62, 63): Group 1: <1.7 mmol/l; Group 2: 1.7–2.19 
mmol/l; Group 3: 2.2–5.59 mmol/l; Group 4: 5.6–11.29 mmol/l; Group 5: 11.3–22.59 mmol/l; 
and Group 6: ≥22.6 mmol/l. To convert TG from mmol/l to mg/dl, multiply by 88.57. In the 
case of each variable, elevated TG groups (Groups 2-6) were compared with the normal TG 
group (Group 1). TG categories were collapsed to three groups (<1.7 mmol/l; 1.7-11.29 
mmol/l; ≥11.3 mmol/l) for the analysis of organ failure because of the low event number.  
Seventy-three variables were collected from each AP case. The analysis was performed 
on 42,655/52,268 available data. Local complications, organ failure, and severity were defined 
based on the revised Atlanta classification (6). The 716 cases investigated showed the same 
epidemiological and major outcome distribution as the total cohort (1435 cases), demonstrating 
that our patient population represents a normal AP cohort (Fig. 2).  
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Fig. 2. Representation of enrolled patients (n=716) compared to the entire cohort (n=1435). A) Gender 
distribution of acute pancreatitis (AP) cases. B) Age distribution of AP cases in males and females. C) Severity 
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distribution of AP cases. D) Mortality of AP cases in the different severity groups. E) Length of hospitalization 
of AP cases in the different severity groups. F) Etiology distribution of AP cases (a: p=0.007). ERCP=endoscopic 
retrograde cholangiopancreatography. N numbers (n) indicate the total number of cases in each triglyceride group.  
 
The registry received ethical permission from the Scientific and Research Ethics 
Committee of the Medical Research Council (22254-1/2012/EKU) in 2012, and all the patients 
provided written informed consent to participate. The study protocol conforms to the ethical 
guidelines of the Declaration of Helsinki updated in 2013 as reflected in a priori approval by 
the institution's human research committee. 
 
Statistical analysis 
Prior to analysis of the dataset, descriptive statistical tools were used to describe the 
basic characteristics. Mean and standard error of the mean were calculated for continuous 
variables, whereas the incidence in each group was determined for categorical variables. 
Depending on the distribution of the data, the independent Student’s t-test or Mann–Whitney 
U test was used to evaluate differences between continuous parameters. The chi-square test or 
Fisher’s exact test was conducted to analyze the relations between categorical variables. We 
compared the confidence intervals (CI) of the proportions to investigate differences in the 
incidence of moderately severe cases between groups. A p-value less than 0.05 (≤ 0.05) was 
determined as statistically significant. All analyses were performed using IBM-SPSS 
Statistical Software Version 25 (IBM Corporation, Armonk, NY, USA). 
 
III.4. Results 
In our cohort, 30.6% (n=219) of the patients presented with elevated TG level (≥1.7 
mmol/l). HTG was significantly and dose-dependently linked to younger age and male gender 
(Fig. 3A-C). In 7.7% of AP cases (n=55), TG level was above 11.3 mmol/l, which is considered 
as a causative etiological factor (24, 63). In 56.4% of these cases, HTG-AP patients had no 
other etiology described; however, raised TG level was also accompanied by alcohol in 38.2% 
of these cases and by biliary etiology in 5.4%, showing that HTG-AP is associated with other 
etiologies in a substantial number of cases (Fig. 3D). 
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Fig. 3. Epidemiology and etiology. A) Age distribution of acute pancreatitis (AP) cases in males and females. 
B) Age distribution of triglyceride (TG) groups (a, c, d: p=<0.001; b: p=0.010). C) Gender distribution of 
triglyceride groups (e: p=0.002; f, g: p<0.001). D) Etiology. HTG=hypertriglyceridemia; ERCP=endoscopic 
retrograde cholangiopancreatography. N numbers (n) indicate the total number of cases in each triglyceride group. 
 
Data from patients’ medical history revealed that HTG is significantly and dose-
dependently linked to obesity and DM (Fig. 4B, C); however, there is no relation to CP and the 
Charlson comorbidity index (CCI) (69) (Fig. 4A, D). The amount of previous AP in the medical 
history was higher in the HTG group compared to the normal TG group (Fig. 4A).  
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Fig. 4. Patients’ medical history of triglyceride groups. A) Acute pancreatitis (AP) and chronic pancreatitis 
(CP) in patients’ medical history (a: p=0.026; b: p=0.023). B) Obesity (body mass index (BMI), kg/m2) (c: 
p=0.006; d: p=0.001). C) Diabetes mellitus in medical history (e: p=0.046; f: p=0.016; g: p=0.026; h: p<0.001). 
D) Charlson comorbidity index (CCI). N numbers (n) indicate the total number of cases in each triglyceride group. 
 
General symptoms of AP and physical examination on admission (incidence, duration 
and intensity of pain, nausea, vomiting, abdominal tenderness and guarding, and blood 
pressure) have not shown a significant link to elevated TG level (Fig. 5A, B). However, HTG 
was significantly related to increased heart rate (Fig. 5C). Regarding the laboratory parameters 
on admission showing significant differences with HTG, amylase, lipase, sodium, and calcium 
were associated inversely; however, glucose, C-reactive protein (CRP), cholesterol, red blood 
cell count (RBC), hemoglobin, and hematocrit were related in parallel with TG level (Fig. 6). 
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Fig. 5. Symptoms and physical findings on admission in the different triglyceride (TG) groups. A) Incidence, 
duration before admission and intensity of pain. Nausea, vomiting, abdominal tenderness and abdominal guarding 
(a: p=0.025; b: p=0.036). B) Systolic and diastolic blood pressure (Hgmm) (c: p=0.012). C) Heart rate (BPM) (d, 
e: p=0.010). N numbers (n) indicate the total number of cases in each triglyceride group. 
 
On admission, laboratory parameters consistent with cholestasis suggested that HTG is less 
common in cases with biliary etiology (Fig. 7). The parallel rise in gamma-glutamyltransferase 
(γGT) and TG levels confirms that alcohol consumption is linked to HTG (Fig. 7D). White 
blood cell count (WBC), thrombocyte, lactate dehydrogenase (LDH), blood urea nitrogen 
(BUN), creatinine, and potassium had no significant relation to HTG (Fig. 8).  
The rate of local complications, including peripancreatic fluid collection, pancreatic 
necrosis, and DM was significantly and dose-dependently increased with TG level (Fig. 9B-
E); however, pancreatic pseudocysts did not show significant differences between the 
investigated groups above 2.2 mmol/l (Fig. 9F). 
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Fig. 6. Laboratory parameters on admission significantly associated with hypertriglyceridemia. A) 
Triglyceride groups (1–6). B) Amylase (U/l) (a: p=0.036; b, c, e: p=<0.001; d: p=0.009). C) Lipase (U/l) (f: 
p=0.017; g: p=0.001). D) Sodium (mmol/l) (h, i: p=<0.001; j: p=0.005). E) Calcium (mmol/l) (k: p=0.012). F) 
Glucose (mmol/l) (l, m: p=<0.001). G) C-reactive protein (CRP, mg/l) (n: p=0.021; o: p=0.014). H) Cholesterol 
(mmol/l) (p: p=0.008; q: p=0.006; r, s: p<0.001). I) Red blood cell count (RBC, T/l) (t: p=0.017; u: p=0.004) J) 
Hemoglobin (G/l) (v: p=0.008; w: p<0.001; x: p=0.002). K) Hematocrit (%) (y: p=0.009; z: p=0.014). N numbers 
(n) indicate the total number of cases in each triglyceride group. 
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Fig. 7. Laboratory parameters representing hepatobiliary system on admission in the different triglyceride 
groups. A) Triglyceride groups (1–6). B) Aspartate transaminase (ASAT, U/l) (a: p=0.050; b: p=0.037). C) 
Alanine transaminase (ALAT, U/l). D) Gamma-glutamyltransferase (γGT, U/l). E) Alkaline phosphatase (ALP, 
U/l) (c: p=0.028; d: p=0.003). F) Total bilirubin (umol/l). N numbers (n) indicate the total number of cases in each 
triglyceride group. 
 
 
Fig. 8. Laboratory parameters on admission without significant alterations with hypertriglyceridemia. A) 
White blood cell count (WBC, G/l). B) Thrombocyte (G/l). C) Lactate dehydrogenase (LDH, U/l). D) Blood urea 
nitrogen (BUN, mmol/l). E) Creatinine (umol/l). F) Potassium (mmol/l). N numbers (n) indicate the total number 
of cases in each triglyceride group. 
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Organ failure, including heart and renal failure, and maximum CRP level were 
significantly and dose-dependently raised by TG level (Fig. 10A, C, E, F); however, respiratory 
failure and maximum WBC count did not show any significant differences by HTG (Fig. 10B, 
D).  
 
 
Fig. 9. Local pancreatic complications in the different triglyceride groups. A) Triglyceride groups (1–6). B) 
Local pancreatic complications (a, b: p<0.001). C) Peripancreatic fluid collection (c: p=0.004; d: p<0.001). D) 
Pancreatic necrosis (e: p=0.003; f: p<0.001). E) Diabetes mellitus as complication (g: p=0.004; h: p<0.001; i: 
p=0.011). F) Pancreatic pseudocyst (j: p=0.031). AP=acute pancreatitis. N numbers (n) indicate the total number 
of cases in each triglyceride group. 
 
As regards severity, TG level above 11.3 mmol/l was associated with a significantly 
higher rate of moderately severe AP and longer hospital stay, whereas TG level above 22.6 
mmol/l was significantly related to severe AP as well (Fig. 11A, B). Due to the low event rate, 
the effect of HTG on mortality could not be determined (Fig. 11A). Detailed values of charts 
and statistical parameters are shown in Tables 1 and 2. Plasmapheresis was carried out in 36.4% 
(20/55) of the HTG-AP cases; 85% of these patients had an initial TG level higher than 22.6 
mmol/l, and the average TG level was 70.1±10.0 mmol/l. 
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Fig. 10. Systemic inflammatory effect and organ failure in the different triglyceride groups. A) Maximum 
C-reactive protein (Max CRP, mg/l) (a, c: p<0.001; b: p=0.029). B) Maximum white blood cell count (Max WBC, 
G/l). C) Organ failure (d: p=0.001). D) Respiratory failure. E) Heart failure (e: p=0.007). F) Renal failure (f: 
p=0.002). AP=acute pancreatitis. N numbers (n) indicate the total number of cases in each triglyceride group. 
Group 1: <1.7 mmol/l; Group 2: 1.7–2.19 mmol/l; Group 3: 2.2–5.59 mmol/l; Group 4: 5.6–11.29 mmol/l; Group 
5: 11.3–22.59 mmol/l; Group 6: ≥22.6 mmol/l. 
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Fig. 11. Outcomes in the different triglyceride (TG) groups. A) Length of hospitalization (LOH, day) and 
mortality (n) (a: p=0.034; b: p=0.001). B) Severity (c: p=0.001; d: p<0.001). Moderately severe acute pancreatitis 
(AP) cases (Group 1: 22.6% (95% CI: 19%–26.6%); Group 5: 66.7% (95% CI: 38.4%–88.2%); Group 6: 47.4% 
(95% CI: 31.0%–64.2%)). Severe AP cases (e: p=0.006). N numbers (n) indicate the total number of cases in each 
triglyceride group. 
 
III.5. Discussion 
HTG-AP has grown in incidence and importance. According to the previously 
published literature (64, 65), HTG is the third most common cause of AP (7.7%). However, it 
seems more than likely that the incidence of HTG-AP is higher than is usually recorded. The 
prospective multicenter, international AP cohort run by the HPSG revealed that TG 
measurement is performed in just 50% (716/1435) of AP cases within the first three days of 
admission, and most probably this rate is even lower in centers that provide no data. 
Furthermore, our data also confirmed additional etiological factors (alcohol and biliary disease) 
besides HTG in 43.6% of HTG-AP cases, and showed a dose-dependent relation between 
obesity (body mass index), pre-existing DM, and HTG. These data also suggest a higher 
incidence rate since physicians finding an etiological factor behind AP usually do not undertake 
further investigation. Our data are in accordance with Scherer et al., who recommend that HTG-
AP should be suspected in the case of significant alcohol consumption, poorly controlled DM, 
and metabolic syndrome, including obesity (62). Although our data clearly show that biliary 
obstruction may be associated with HTG, serum TG was measured in just 44.3% (266/601) of 
the biliary AP cases. Furthermore, in the case of biliary AP, there is no recommendation for 
TG measurement.  
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 Our data analysis confirmed results published by Zheng et al. (25) and Zhu et al. (26) 
which show that HTG is significantly linked to younger age and male gender. This is not 
surprising, since underlying genetic abnormalities behind HTG contribute to younger 
manifestation, and alcohol-related HTG affects the male gender and younger ages more (3, 62, 
70). In contrast, biliary etiology is accompanied by a higher rate for the female gender and 
older population (3, 71).  
 Diagnosing AP in the presence of HTG can be challenging due to in vitro interference 
between plasma TG levels above 5.6 mmol/l (with grossly turbid plasma) and determination 
of amylase and lipase activities (72, 73). Our data confirmed a significant reduction of amylase 
and lipase levels with the elevation of TG. Furthermore, case reports have been published by 
Singh et al. (74) and Sotello et al. (75), presenting HTG-AP patients with normal amylase and 
lipase levels.  
 Our analysis has shown that local complications and organ failure were significantly 
increased by HTG, as published in previous reports and a recent meta-analysis by Kiss et al. 
(19, 20, 23, 24, 67). Nawaz et al. (21) confirmed that TG above 2.3 mmol/l is independently 
associated with persistent organ failure on a multivariate analysis controlling for age, gender, 
body mass index, diabetes, and alcohol etiology, whereas Szentesi et al. (76) revealed that 
hyperlipidemia was an independent predictive factor for local complications and new-onset 
DM. Although we could not confirm a significantly higher risk of pancreatic pseudocysts in 
the case of TG above 2.2 mmol/l, it is well known that pseudocysts usually occur more than 
four weeks after the onset of AP, and the average hospital stay was 10.4±0.3 days in our cohort 
(6).  
Based on our data analysis, severity of AP and LOH were significantly increased by 
HTG (20-26). Navarro et al. (28) and Goyal et al. (27) also confirmed that HTG aggravates the 
severity of AP compared to biliary and alcoholic etiology, respectively. The underlying 
mechanism is clearly complex. Unsaturated free fatty acids (UFAs) generated from TG are 
responsible for cell injury by membrane lipid peroxidation, long-lasting cytosolic Ca2+ 
elevation, and mitochondrial damage (17, 77). In the case of additional alcohol consumption, 
non-oxidative ethanol metabolites FAEEs contribute to the persistent Ca2+ elevation and drop 
in ATP level (11, 78). Additionally, the raised plasma viscosity caused by 
hyperchylomicronemia leads to ischemia and acidosis in the pancreatic capillaries (18). This 
pathologic environment results in an early trypsinogen activation and pancreatic lipase leakage, 
leading to further free fatty acid (FFA) release and accumulation (18, 77, 79). Moreover, UFAs 
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bring about a systemic pro-inflammation through increased mRNA production of tumor 
necrosis factor-alpha (TNF-α) and neutrophil chemoattractants, thereby increasing the severity 
of AP (17). In our cohort, heart rate and maximum CRP were significantly raised by HTG, 
suggesting the systemic inflammatory effect of relatively high TG levels. In contrast, 
Pothoulakis et al. (80) and Balachandra et al. (81) reported that HTG does not worsen severity. 
Furthermore, Wang et al. showed that longer hospital stay was associated with higher TG level, 
but the difference was not significant (23).  
The overall mortality of AP is ~1% based on the literature (3, 25) and 1.5% in our 
cohort, but we could not perform a further subgroup analysis because of the low event number. 
Zhu et al. (26) and Deng et al. (82) confirmed that HTG-AP is accompanied by a significantly 
higher rate of mortality among severe AP cases compared to biliary AP and non-HTG etiology, 
respectively. However, Tai et al. (22) showed that mortality was similar in HTG-AP and biliary 
AP groups in a general AP cohort. 
In our cohort, plasmapheresis was carried out in 36.4% of the HTG-AP cases. Although 
our data clearly suggest that the severity of AP is significantly elevated above the 11.3 mmol/l 
TG level, the average TG level was 70.1±10.0 mmol/l in patients with plasmapheresis, and 
85% of these cases had a TG level over 22.6 mmol/l. We could not state any further conclusions 
regarding the therapy because of incomplete data and lack of randomization as a result of the 
cohort feature of the dataset. Overall and in most cases, TG-lowering therapy such as 
plasmapheresis and glucose-heparin-insulin (GLU-HEP-INS) administration is performed 
above a TG level of 40 mmol/l. In order to solve this unmet need, the HPSG has initiated a 
prospective randomized clinical trial to investigate different lipid-lowering therapies in AP 
(58). 
 Our study has several limitations. Although all data were collected prospectively, all 
questions were raised retrospectively. Cases were included in the analysis with TG 
measurement within the first three days of admission, but unfortunately only 50% of the entire 
cohort met the inclusion criteria. We attempted to minimize these limitations by comparing the 
epidemiological and major outcome distributions of the data analyzed and the whole cohort. 
We confirmed that the population under investigation represents a normal AP cohort. 
 
III.6. Conclusion 
Our results confirm that HTG dose-dependently increases the complications and severity of 
AP, and highlight the necessity of better awareness of an accurate determination of causative 
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and influencing risk factors in AP regardless of the etiology. Our data suggest that lipid-
lowering therapy may be important clinically at a much lower TG level than we previously 
thought. 
 
Table 1. Values. Values on charts in the different triglyceride groups (Group 1: <1.7 mmol/l; Group 2: 1.7–
2.19 mmol/l; Group 3: 2.2–5.59 mmol/l; Group 4: 5.6–11.29 mmol/l; Group 5: 11.3–22.59 mmol/l; Group 6: 
≥22.6 mmol/l). DM=diabetes mellitus.  
 
Parameter Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
 FIG. 3 
Gender, male % 52.9 52.6 71.4 90.0 75.0 87.2 
FIG. 4 
Obesity, body mass index, kg/m2 (SE) 27.4 (0.3) 28.4 (0.8) 28.7 (0.7) 30.4 (0.9) 30.3 (1.1) 30.6 (1.0) 
DM in the personal history, % 13.4 23.2 24.0 30.0 31.3 38.5 
Charlson comorbidity index (CCI) (SE) 1.3 (0.1) 1.6 (0.2) 1.5 (0.2) 1.9 (0.4) 1.5 (0.3) 1.4 (0.2) 
 FIG. 5 
Blood pressure – systolic, Hgmm (SE) 139.5 (1.1) 139.9 (2.6) 140.5 (2.8) 146.5 (4.7) 133.8 (6.3) 141.3 (4.2) 
Blood pressure – diastolic, Hgmm (SE) 82.2 (0.7) 83.7 (1.5) 85.2 (2.2) 89.5 (3.1) 80.8 (5.6) 83.3 (2.6) 
Heart rate, BPM (SE) 81.6 (0.7) 82.3 (2.3) 83.5 (2.1) 87.0 (2.8) 93.3 (4.1) 89.3 (3.4) 
FIG. 6 
Amylase, U/l (SE) 
1203.2 
 (55.6) 
857.2 
 (114.8) 
884.7 
 (151.3) 
488.6 
 (86.7) 
501.6 
 (163.9) 
488.4 
 (113.5) 
Lipase, U/l (SE) 
2993.2 
 (209.5) 
3290.7 
 (741.6) 
2942.5 
 (708.9) 
1376.5 
 (298.9) 
2040.2 
 (619.3) 
1543.6 
 (485.4) 
Sodium, mmol/l (SE) 138.3 (0.2) 138.1 (0.8) 139.0 (0.6) 134.4 (1.1) 133.3 (0.7) 133.3 (2.5) 
Calcium, mmol/l (SE) 2.3 (0) 2.3 (0) 2.3 (0) 2.2 (0.1) 2.6 (0.5) 2.0 (0.2) 
Glucose, mmol/l (SE) 7.9 (0.1) 8.2 (0.5) 8.6 (0.5) 11.2 (1.1) 12.1 (1.5) 10.2 (1.0) 
C-reactive protein (CRP), mg/l (SE) 46.0 (3.2) 37.2 (6.9) 54.5 (10.5) 90.5 (21.2) 107.3 (39.7) 85.5 (21.9) 
Cholesterol, mmol/l (SE) 4.4 (0.1) 4.9 (0.2) 5.4 (0.4) 9.3 (2.9) 11.2 (1.6) 21.6 (2.4) 
Red blood cell count (RBC), T/l (SE) 4.7 (0) 4.5 (0.1) 4.7 (0.1) 5.0 (0.1) 5.3 (0.2) 4.7 (0.1) 
Hemoglobin, G/l (SE) 142.0 (1.0) 138.0 (4.0) 149.4 (2.8) 158.1 (3.4) 165.1 (5.4) 150.7 (4.7) 
Hematocrit, % (SE) 41.8 (0.3) 41.0 (1.1) 42.5 (0.7) 44.8 (0.8) 46.2 (1.6) 41.1 (0.8) 
FIG. 7 
Aspartate transaminase (ASAT), U/l (SE) 152.4 (11.4) 151.9 (52.0) 103.5 (22.7) 58.6 (16.9) 89.5 (45.7) 78.7 (20.2) 
Alanine transaminase (ALAT), U/l (SE) 147.8 (11.2) 139.2 (42.7) 105.7 (19.5) 76.0 (31.6) 92.0 (40.3) 60.2 (18.2) 
Gamma-glutamyltransferase(γGT), U/l 
(SE) 
299.7  
(20.3) 
308.8  
(53.3) 
351.1  
(76.9) 
455.8 
 (145.6) 
370.4  
(89.6) 
526.7 
 (201.0) 
Alkaline phosphatase (ALP), U/l (SE) 183.4 (9.8) 191.5 (25.9) 154.2 (15.8) 156.6 (45.0) 135.9 (17.2) 98.7 (8.5) 
Total bilirubin, umol/l (SE) 31.6 (1.6) 37.7 (7.2) 24.4 (3.6) 29.7 (7.3) 23.2 (5.2) 20.0 (3.8) 
FIG. 8 
White blood cell count (WBC), G/l (SE) 13.1 (0.2) 12.6 (0.8) 14.0 (0.8) 14.0 (0.8) 14.8 (2.1) 14.0 (0.8) 
Thrombocyte, G/l (SE) 249.3 (5.2) 248.0 (12.9) 259.8 (14.1) 220.2 (20.0) 211.5 (18.3) 251.6 (15.4) 
Lactate dehydrogenase (LDH), U/l (SE) 446.2 (15.1) 503.1 (84.5) 433.9 (45.1) 355.3 (36.2) 447.6 (63.2) 448.3 (67.2) 
Blood urea nitrogen (BUN), mmol/l (SE) 6.3 (0.2) 5.8 (0.3) 6.7 (0.7) 6.0 (0.8) 6.7 (1.4) 5.6 (0.5) 
Creatinine, umol/l (SE) 82.1 (1.7) 79.1 (3.6) 101.6 (12.2) 99.3 (11.4) 75.1 (9.3) 105.3 (17.4) 
Potassium, mmol/l (SE) 4.1 (0) 4.1 (0.1) 4.0 (0.1) 4.1 (0.1) 4.1 (0.1) 4.3 (0.2) 
FIG. 9 
Local pancreatic complications, % 24.3 29.8 32.5 36.7 68.8 61.5 
Peripancreatic fluid collection, % 21.9 24.6 27.3 26.7 56.3 56.4 
Pancreatic necrosis, % 6.2 10.5 6.5 13.3 31.3 25.6 
DM as complication, % 1.8 1.8 3.9 13.3 31.3 10.3 
Pancreatic pseudocyst, % 6.8 15.8 11.7 10.0 12.5 7.7 
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Table 2. Statistics. P-values of parameters analyzed in the different triglyceride (TG) groups (Normal: <1.7 
mmol/l; Group 2: 1.7–2.19 mmol/l; Group 3: 2.2–5.59 mmol/l; Group 4: 5.6–11.29 mmol/l; Group 5: 11.3–22.59 
mmol/l; Group 6: ≥22.6 mmol/l). Significant differences (p≤0.05) are in grey and emboldened. AP=acute 
pancreatitis; CP=chronic pancreatitis; DM=diabetes mellitus. 
 
Parameter 
Normal vs  
Group 2 
Normal vs 
Group 3 
Normal vs 
Group 4 
Normal vs 
Group 5 
Normal vs 
Group 6 
 FIG. 3 
Age 0.290 <0.001 0.010 0.075 <0.001 
Gender 0.967 0.002 <0.001 0.081 <0.001 
FIG. 4 
AP in the medical history 0.548 0.026 0.185 1.000 0.130 
CP in the medical history 0.764 0.023 0.391 1.000 0.251 
Obesity (body mass index) 0.229 0.056 0.006 0.057 0.001 
DM in the medical history 0.046 0.016 0.026 0.058 <0.001 
Charlson comorbidity index (CCI) 0.247 0.345 0.085 0.276 0.215 
 FIG. 5 
Abdominal pain 0.583 0.602 1.000 1.000 1.000 
Duration of abdominal pain before 
admission 
0.051 0.025 0.135 0.420 0.226 
Intensity of abdominal pain 0.656 0.850 0.903 0.824 0.671 
Nausea 0.144 0.615 0.413 0.544 0.288 
Vomiting 0.788 0.119 0.691 0.618 0.222 
Abdominal tenderness 0.348 0.701 0.036 0.146 0.608 
Abdominal guarding 0.844 0.618 0.512 0.661 0.784 
Blood pressure – systolic 0.902 0.742 0.159 0.431 0.697 
Blood pressure – diastolic 0.476 0.215 0.012 0.734 0.712 
Heart rate 0.758 0.334 0.087 0.010 0.010 
FIG. 6 
Amylase 0.036 <0.001 <0.001 0.009 <0.001 
Lipase 0.220 0.117 0.017 0.825 0.001 
Sodium 0.929 0.072 <0.001 <0.001 0.005 
Calcium 0.509 0.371 0.257 0.860 0.012 
Glucose 0.506 0.091 <0.001 <0.001 0.087 
C-reactive protein (CRP) 0.926 0.698 0.021 0.067 0.014 
Cholesterol 0.126 0.008 0.006 <0.001 <0.001 
Red blood cell count (RBC) 0.155 0.990 0.017 0.004 0.850 
Hemoglobin 0.995 0.008 <0.001 0.002 0.070 
Hematocrit 0.368 0.324 0.009 0.014 0.575 
      
      
      
Table 1 (continued) 
FIG. 10 
Maximum C-reactive protein (CRP), mg/l 
(SE) 
135.8 (5.0) 113.2 (13.1) 137.8 (15.5) 215.2 (25.3) 228.8 (38.3) 232.4 (22.7) 
Maximum white blood cell count (WBC), 
G/l (SE) 
14.6 (0.3) 13.4 (0.7) 16.7 (1.2) 14.6 (0.9) 15.9 (1.5) 14.5 (0.7) 
Organ failure, % 4.8 1.8 7.8 3.3 6.7 20.5 
Respiratory failure, % 3.6 3.7 9.3 
Heart failure, % 1.0 1.8 7.4 
Renal failure, % 1.8 3.7 11.1 
FIG. 11 
Mild acute pancreatitis, % 74.7 71.4 66.2 63.3 33.3 39.5 
Moderately severe acute pancreatitis, % 22.6 26.8 28.6 33.3 66.7 47.4 
Severe acute pancreatitis, % 2.6 1.8 5.2 3.3 0 13.2 
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Table 2 (continued) 
FIG. 7 
Aspartate transaminase (ASAT) 0.050 0.070 0.037 0.321 0.165 
Alanine transaminase (ALAT) 0.094 0.537 0.095 0.939 0.148 
Gamma-glutamyltransferase (γGT) 0.627 0.704 0.320 0.140 0.575 
Alkaline phosphatase (ALP) 0.514 0.631 0.028 0.968 0.003 
Total bilirubin 0.652 0.056 0.512 0.555 0.060 
FIG. 8 
White blood cell count (WBC) 0.492 0.213 0.370 0.443 0.324 
Thrombocyte 0.940 0.458 0.711 0.265 0.914 
Lactate dehydrogenase (LDH) 0.557 0.524 0.221 0.593 0.975 
Blood urea nitrogen (BUN) 0.799 0.520 0.395 0.964 0.233 
Creatinine 0.534 0.246 0.081 0.147 0.146 
Potassium 0.673 0.463 0.990 0.847 0.145 
FIG. 9 
Local pancreatic complications 0.365 0.128 0.130 <0.001 <0.001 
Peripancreatic fluid collection 0.651 0.297 0.545 0.004 <0.001 
Pancreatic necrosis 0.255 1.000 0.129 0.003 <0.001 
DM as complication 1.000 0.210 0.004 <0.001 0.011 
Pancreatic pseudocyst 0.031 0.133 0.459 0.311 0.744 
FIG. 10 
Maximum C-reactive protein (CRP) 0.147 0.886 <0.001 0.029 <0.001 
Maximum white blood cell count 
(WBC) 
0.197 0.079 0.982 0.398 0.999 
Organ failure 0.498 0.273 1.000 0.535 0.001 
Respiratory failure 0.979 0.065 
Heart failure 0.416 0.007 
Renal failure 0.221 0.002 
FIG. 11 
Length of hospitalization 0.598 0.221 0.969 0.034 0.001 
Severity 0.762 0.221 0.372 0.001 <0.001 
Severe AP 1.000 0.267 0.566 1.000 0.006 
 
FIG. 2  FIG. 11 
Parameter 
Total cohort vs 
analyzed data 
 
TG group Moderately severe AP 95% CI 
Gender 0.363  1 22.6% 19.0% 26.6% 
Age 0.369  2 26.8% 15.8% 40.3% 
Severity 0.505  3 28.6% 18.8% 40.0% 
Severe AP 0.256  4 33.3% 17.3% 52.8% 
Mortality 0.148  5 66.7% 38.4% 88.2% 
Length of 
hospitalization 
0.084 
 
6 47.4% 31.0% 64.2% 
Etiology 0.007      
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IV. CHILDREN ARE NOT SMALL ADULTS 
 
Since childhood onset pancreatitis is a different entity compared with pancreatitis in 
adults, there are remarkable differences in incidence, etiology, clinical course and severity 
between the two age groups (38, 46, 83). However, trials are limited and based on small cohorts 
or completely lacking in children. Therefore, most of the pediatric guidelines are adopted from 
the adult protocols.  
 
IV.1. THE PINEAPPLE STUDY 
 
IV.1.1. Introduction 
Several publications describe an increasing incidence of AP in both children and adults 
(45, 46, 84-87). Although the overall incidence of APP is below 1 per 100,000 worldwide, two 
major studies have proven that the incidence of AP is not much less in children than in adults 
(3.6–13.2 per 100,000 versus 13-45 per 100,000) (44-46). Diagnosis of AP requires at least 
two of the following parameters: (1) abdominal pain, (2) serum amylase and/or lipase values ≥ 
3 times upper limits of normal, and (3) characteristic imaging findings for AP (36, 37). A 
retrospective trial in Pittsburgh revealed a close relationship between the number of serum 
amylase and lipase measurements and the rising incidence of the disease (44). Their data 
showed that the increased pancreatic enzyme testing could account for 94% of the change in 
all childhood AP admissions, suggesting that APP is an underdiagnosed disease. 
There are factors which make the diagnosis of APP challenging: (i) abdominal pain is 
a common complaint in kids; 50% of the cases are in the category of pain-predominant 
functional gastrointestinal disorder with no significant morbidity (88); (ii) hospitals cannot 
afford to measure serum amylase/lipase in every child experiencing abdominal pain (88); (iii) 
the clinical course of AP, pancreatic exocrine function, and radiological preferences differ by 
age (38, 46, 89); (iv) pediatric trials are lacking, so diagnostic criteria for APP are based on 
adult protocols and no evidence-based medicine (EBM) guidelines are available to provide 
proper instruction concerning the necessity of diagnostic tests for AP during abdominal pain in 
children (37). Therefore, most of the ordered pancreatic enzyme tests and abdominal 
ultrasonography (US) are based on individual pediatrician experience, and APP may be delayed 
or underdiagnosed as a result of the decreased awareness of diagnostic workup (90). Overall, 
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international observational clinical trials are crucially needed to understand the most common 
clinical characteristics of AP in children.  
 
IV.1.2. Aims 
We aimed to perform a review of our current clinical practice in order to estimate the 
real incidence of APP and to provide a fast, simple, and authentic scoring system that helps to 
evaluate (in a reliable and cost-efficient way) the necessity of pancreatic enzyme tests and 
abdominal US when a child has abdominal pain.  
 
IV.1.3. Methods 
We initiated an international, multicenter, clinical trial called PINEAPPLE. The study 
has been established and drafted by the HPSG. The trial consists of a retrospective and a 
prospective subtrial.  
PINEAPPLE-R is a retrospective review of electronic computerized records of children 
(under 18 years old) appearing at emergency units, centered around their clinical symptoms, 
serum pancreatic enzyme measurement (sPEM), and abdominal imaging examinations. 
Inclusion and exclusion criteria are shown in Table 3. Diagnosis and data concerning 
abdominal pain [yes/no] are required for all patients appearing at ER units. Diagnosis of 
abdominal pain is decided based on the doctor’s record. If the patient had abdominal pain, 
information about basic clinical symptoms (vomiting, nausea), sPEM (either amylase or lipase; 
if yes: amylase/lipase [normal/increase less than 3x/increase more than 3x the upper threshold]) 
and imaging examination of the pancreas (if yes: type and result) are obligatory. Data are 
collected into a uniform harmonized Excel sheet.  
PINEAPPLE-P is the prospective part of the study and has a questionnaire-style data 
collection method. Each 
patient under 18 years old 
presenting at ER units with 
acute abdominal pain is 
enrolled to the study 
regardless of the etiology 
(Table 3). Acute abdominal 
pain was defined as pain of 
less than one month duration. 
Table 3. Inclusion and exclusion criteria of the PINEAPPLE study. 
  PINEAPPLE-R PINEAPPLE-P 
Inclusion 
criteria 
• Age under 18 years old 
• Accurate electronic data 
mentioned in the protocol 
• Age under 18 years old 
• Acute abdominal pain 
 
 
Exclusion 
criteria 
• Age above 18 years old 
• Inaccurate electronic data 
mentioned in the protocol 
• Age above 18 years old 
• No or chronic abdominal 
pain (91) 
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Detailed pediatric patients’ data are collected via a questionnaire, sPEM and abdominal US are 
performed in all cases (Table 4). Patients and parents must be informed accordingly, and the 
‘informed consent form’ is required to be signed.  
The definition of APP is based on the fulfillment of ‘2 out of 3’ of the following criteria: 
(i) abdominal pain compatible with AP; (ii) serum amylase and/or lipase ≥3x upper limit of 
normal; (iii) characteristic findings of AP by abdominal imaging (35, 36). 
 
Table 4. Summary of clinical data required for PINEAPPLE-P. AP=acute pancreatitis; CP=chronic 
pancreatitis; AIP=autoimmune pancreatitis; PC=pancreatic cancer; US=ultrasonography; CT=computed 
tomography. 
 
1. Patient personal details 
Gender  
 
Male/female 
2. Medical history 
(a) Family medical history 
Pancreas disorders in family history: AP/CP/AIP/PC 
 
Other diseases in family history 
 
 
Yes/no/unknown, if yes: relationship to 
the patient 
Yes/no/unknown, if yes: description of 
them 
(b) Personal medical history 
Known diseases  
 
Abdominal surgery  
 
New medications taken in the last 2 weeks  
 
Medications taken regularly 
 
New symptoms, diagnosed diseases in the last 2 weeks  
 
New diet, change in diet in the last 2 weeks  
Any events strongly affecting the child emotionally in the last 2 
weeks  
Change in the environment of the child in the last 2 weeks  
Any other event in the last 2 weeks 
Has the patient had any examination concerning abdominal pain?  
Length of breast milk feeding 
 
Yes/no/unknown, if yes: description of 
them 
Yes/no/unknown, if yes: description of 
the surgery 
Yes/no/unknown, if yes: description of 
them 
Yes/no/unknown, if yes: description of 
them 
Yes/no/unknown, if yes: description of 
them 
Yes/no/unknown, if yes: description of it 
 
Yes/no/unknown, if yes: description of it 
Yes/no/unknown, if yes: description of it 
Yes/no/unknown, if yes: description of it 
Yes/no/unknown, if yes: description of it 
Number of months/unknown 
3. Complaints, symptoms 
(a) Abdominal pain 
How many hours have passed since the pain started?  
Intensity 
Tendency  
 
Continuity 
 
Forced posture  
Nature  
Location  
 
 
Number of hours/unknown 
Number: 1–10 scale/unknown 
Decreasing/intensifying/stagnating/ 
unknown 
Continuous/intermitting/changing/ 
unknown 
Yes/no/unknown 
Dull/sharp/cramping/unknown 
Diffuse/localized/unknown; if localized: 
region (1-9) 
(b) In the case of abdominal pain lasting longer than 48 hours 
Was everyday activity influenced?  
Did the child wake up at night because of the pain?  
 
Yes/no/unknown 
Yes/no/unknown 
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Table 4. (continued) 
In which part of the day did the pain appear mostly?  
 
 
Was it related to eating? 
Unrelated/after waking up/in the 
morning/in the afternoon/in the 
evening/at night/unknown 
Yes/no/unknown; if yes: before/while/ 
after 
(c) Other complaints 
Nausea  
Vomiting  
 
Fever 
 
Appetite  
Weight loss  
 
 
Jaundice  
Stool  
 
Yes/no/unknown 
Yes/no/unknown; if yes: How many 
times? Content of cast? 
Yes/no/unknown; if yes: Since when? 
Temperature? (C°) 
Good/retained/bad/unknown 
Yes/no/unknown, if yes: How much? 
(kg), How long has it taken? 
(weeks/months) 
Yes/no/unknown 
Normal/diarrhea/constipation/fatty/ 
putrid/undigested food/bloody/mucus/ 
unknown 
4. Physical examination 
Blood pressure  
Heart rate  
Body weight  
Body height  
Respiratory rate  
Body temperature  
Abdominal tenderness  
 
Abdominal guarding  
Jaundice  
Bowel sounds  
 
Number (mmHg) 
Number (BPM) 
Number (kg) 
Number (m) 
Number (/min) 
Number (°C) 
Yes/no, if yes: location of abdominal 
tenderness 
Yes/no 
Yes/no 
No/hypoactive/normal/hyperactive 
5. Laboratory parameters 
Amylase and/or lipase  
 
Number (U/l) 
6. Imaging examinations 
Pancreas abnormalities suggesting AP  
Pancreas abnormalities suggesting CP  
Abdominal US 
Abdominal CT scan 
 
Yes/no 
Yes/no 
Yes/no, if yes: description 
Yes/no, if yes: description 
7. Diagnosis  
8. Diagnosis – main group  
9. Further step Admission/discharged/other 
 
We aim to analyze patient data in different age groups. Association between each 
collected parameter and AP will be determined. Statistical analysis will be carried out by data 
mining methods. The applied methods will be determined based on the main characteristics of 
the collected data, and the most suitable method – or method combination – will be chosen. 
The following data mining methods are being contemplated: logistic regression, discriminant 
analysis, random forest analysis, decision tree, and cluster analysis. ROC (receiver operating 
characteristic) analysis will be performed to evaluate the predictive power of the classification 
algorithm. 
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Four quality control points are established. First, the local clinical research assistant 
must upload the data electronically and confirm that the data are the same as those in the hard 
copy. Second, the local institutional principal investigator (who must have a medical doctoral 
degree) must recheck the uploaded data and confirm their validity and accuracy. Third, the 
central data administrator, who is based at HPSG headquarters, must control the accuracy, and 
finally, the trial leader must go through the details. Patients with inadequate or insufficient data 
will be excluded.  
 The protocols were introduced at our international meeting held in Szeged in 
November 2014, which was attended by some of the best-established pediatric 
pancreatologists. Around 100 clinicians – 60 Hungarians and 40 international investigators 
from 9 different countries – attended. The trial was discussed and the suggested modifications 
have been included. The study has been accepted by the scientific committee of the IAP, and 
is therefore running under the auspices of HPSG and IAP. The PINEAPPLE trial has been 
registered at the ISRCTN registry (ISRCTN35618458), a primary clinical trial registry 
recognized by the World Health Organization (WHO) and the International Committee of 
Medical Journal Editors (ICMJE) which accepts all clinical research studies, providing content 
validation and curation as well as the unique identification number necessary for publication.  
The study received the relevant ethical approval (No.: ad.52857-2/2014) issued by the 
National Hungarian Ethical Authority (ETT TUKEB) in 2014. Completion of the ‘Letter of 
intent’ form is mandatory for registering the participation of each institution. Study 
management strictly follows the Ethical Guidelines for Observational Studies.  
 
IV.1.4. Expected results 
The PINEAPPLE trial is ongoing and expected to be finished by December 2020. The 
PINEAPPLE-R study will aid understanding of our current clinical practice of APP in children 
with abdominal pain in different countries and centers. The PINEAPPLE-P study will provide 
the real incidence of APP and help to establish a fast, simple, and authentic scoring system to 
evaluate the necessity of pancreatic enzyme tests and abdominal US when a child has 
abdominal pain. As of the preparation of the thesis, 48,170 patient records have been enrolled 
into PINEAPPLE-R, and 926 patients have been involved in PINEAPPLE-P. 
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IV.1.5. Discussion 
The ‘2 out of 3’ criterion is used to diagnose AP both in adults and children (abdominal 
pain, sPEM, and abdominal imaging) (36, 37, 39, 40, 42). Therefore, without measuring serum 
pancreatic enzymes and/or performing transabdominal imaging, AP may remain undiagnosed.  
According to previous pediatric studies in AP, abdominal pain is present in 66 to 95% 
of the children with AP (48, 92-97); however, inconsistency and high variability exist between 
the studies. Most of the trials investigating the characteristics of abdominal pain have either 
low numbers or missing parameters causing inconsistencies between their data. Based on the 
review of Bai et al. (38), abdominal pain was most commonly localized to the epigastric region 
(62–89% of cases) (89, 92, 98) and was rarely associated with back pain (<10%) in children 
with AP (48, 94). Radiation to the back was seen only in 1.6–5.6% (95, 97, 98) of the cases. 
Diffuse abdominal pain was found in 12–20% of AP patients (92, 95, 97), guarding in 29–37% 
(92, 94), whereas abdominal distension was reported in 21–46% (92-94, 96, 97). Nausea or 
vomiting was noted in 40–80% of the AP cases (48, 89, 95-101). Other symptoms might be 
fever, ascites, pleural effusion, and jaundice. Symptoms of infants and toddlers are much more 
unspecific: abdominal pain was found in 43%, epigastric tenderness in 57%, and nausea in 29% 
(89). In a study from Pittsburgh, 16% of the infants and toddlers had abdominal distension and 
40% had fever (102).  
In summary, a large, international prospective cohort is necessary to understand the 
complaints and symptoms of AP in children. We have proposed an international observational 
clinical trial to collect a critical mass of data from children with abdominal pain in order to 
develop an EBM guideline concerning the necessity for obtaining serum pancreatic enzyme 
testing and abdominal US in pediatric patients who present at the emergency room with 
abdominal pain. 
 
IV.2. EARLY ENTERAL NUTRITION IN ACUTE PEDIATRIC PANCREATITIS 
 
IV.2.1. Introduction 
Common characteristics in both age groups are that no specific therapy is available to 
treat AP, and the general supportive treatment at the early phase of the disease frequently 
consists of volume resuscitation and NPO diet (35, 36, 39, 40). Although there is clear evidence 
in the literature that appropriate volume therapy is beneficial, the latter treatment is 
questionable. 
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One of the main reasons 
for the debate is that the 
pathogenesis of the disease 
clearly suggests the opposite. 
Irrespective of the etiological 
factors, mitochondrial damage 
and energy depletion are the 
leading intracellular responses 
in the early phase of the disease 
in the exocrine pancreas (11, 
13, 78, 103). Bile acids (7-10), 
fatty acids, and non-oxidative 
ethanol metabolites (FAEEs) 
(11-16) were shown to elevate the intracellular Ca2+ concentration, causing mitochondrial 
damage and a resultant decrease of intracellular ATP concentration (Fig. 12). This leads to 
inhibited fluid and bicarbonate secretion and dysfunction of the cystic fibrosis transmembrane 
conductance regulator (CFTR) Cl¯ channel in the ductal cells with resultant secretory block 
and intrapancreatic trypsinogen activation (11, 12, 104, 105). In addition, hypercatabolism 
secondary to pancreatic and extrapancreatic inflammation further aggravates the energy deficit 
(106). Consequently, restoration of ATP level both in acinar and ductal cells prevents (at least 
in part) the toxic effect of the harmful causative factors noted above (78, 107, 108). These data 
strongly suggest that early energy supply should be favorable for AP patients compared to nil 
energy. Moreover, energy supply given by enteral nutrition in AP patients was shown to be 
beneficial as a first-line treatment compared to TPN for several reasons: (i) EEN significantly 
decreases pathogenic bacteria in the stool and alteration of intestinal flora; (ii) gut plays an 
important role as a barrier in the immune system and EEN is able to optimize intestinal 
permeability; (iii) this mucosal barrier integrity decreases the bacterial translocation from the 
gut, therefore resultant bacteraemia and levels of serum endotoxins are reduced; (iv) EEN has 
a favorable effect on immune dysregulation caused by SAP which can reduce the rate of 
pancreatic infection, systemic inflammatory response syndrome (SIRS) and multiple organ 
dysfunction syndrome as well as duration of ICU stay (34, 106, 109). Accordingly, enteral 
nutrition either via oral, nasogastric- or nasojejunal tube feeding has been shown to be 
beneficial regarding visual analogue pain score, LOH, systemic infection, multi organ failure 
Fig. 12. Early events in acute pancreatitis. Bile acids, fatty acids or 
non-oxidative ethanol metabolites (fatty acid ethyl esthers, FAEEs) 
induce calcium overload, causing mitochondrial damage and a 
resultant decrease in intracellular adenosine triphosphate (ATP) 
concentration both in acinar and ductal cells. This will lead to general 
energy depletion in the pancreas. 
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(MOF), need for surgical interventions, and mortality (29-33, 110-114). Additionally, enteral 
nutrition further improves the outcome of AP if it is started within 48-72 hours (34, 36, 115, 
116). The type of enteral nutrition is administered based on disease severity (117).  
Furthermore, enteral nutrition has already been proven to be beneficial in other 
inflammatory gastrointestinal diseases. The first-line recommendation to induce remission in 
pediatric Crohn’s disease is exclusive enteral nutrition (118). Enteral nutrition could also be 
effective in the maintenance of pediatric inflammatory bowel disease remission (119).  
Regarding AP, three of the recent and most up-to-date guidelines for AP in adults have 
shown the positive effect of early enteral tube feeding in moderately severe and SAP (36, 39, 
40). Moreover, nasogastric tube feeding was shown to be as safe and as effective as nasojejunal 
tube feeding in SAP (114). In the case of patients with predicted mild AP, oral feeding is 
preferred as soon as possible (36, 39, 40). However, no systematic review is available 
concerning the role of EEN in children.  
 
IV.2.2. Aims 
We aimed to review the literature to analyze the effect of EEN versus NPO therapy on 
the outcome of APP, and to aggregate the information in childhood onset AP, leading to a 
higher statistical power and more robust point estimate than is possible from the individual 
studies. 
 
IV.2.3. Methods 
The preferred reporting items for systematic review and meta-analysis protocol 
(PRISMA-P) was followed (120). Our structured literature search was based on the 
participants, intervention, comparison and outcomes (PICO) format [P: patients under the age 
of twenty-one suffering from AP; I: EEN (per os/nasogastric- or nasojejunal tube started within 
24-48 hours); C: NPO therapy (per os/nasogastric- or enteral tube started after 24-48 hours); 
O: length of hospitalization, need for ICU, complications, necessity of antibiotics, 
surgical/non-surgical interventions, and mortality].  
In February 2016, a literature search was performed on the PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and EMBASE (https://www.embase.com) databases 
using the following Medical Subject Headings and search terms: “pediatric” OR “paediatric” 
AND “pancreatitis”. The search was limited to human studies, full-text publications with 
abstracts in English with no time period, resulting in 632 articles altogether (PubMed: 131; 
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EMBASE: 501). The articles were checked separately. Meta-analyses, reviews, case reports 
and articles on CP were excluded and duplicates were removed (Fig. 13). Potentially eligible 
papers were selected, and finally five of them with relevant data on EEN or with NPO therapy  
 
Fig. 13. Flow chart on the methods used in the literature search. 
 
 in APP in patients under 21 years old were included (Table 5). Details in the collected articles 
were checked, and only articles where both EEN and NPO were presented separately were 
used. Two articles met this 
criterion which contained 
three separate data pairs, 
where EEN was compared 
to NPO (Fig. 14A). The 
following parameters were 
collected: LOH, need for 
treatment at ICU, and 
development of SAP. Only 
Table 5. Studies included in the quantitative synthesis. EEN=early 
enterals nutrition; NPO=nil per os; IVF=intravenous fluid; lo=low; 
hi=high. 
Ref. Data Groups n 
Abu-El-Haija et al., 2016 (121) yes 
EEN 24 
NPO 14 
Flores-Calderón et al., 2009 (122)   18 
Goh et al., 2003 (100)   12 
Raizner et al., 2013 (123)   7 
Szabo et al., 2015 (124) 
yes 
EEN + IVF lo 55 
NPO + IVF lo 20 
yes 
EEN + IVF hi 96 
NPO + IVF hi 30 
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one of the three investigated parameters (LOH) contained a minimum of three items, which 
were analyzed statistically.  
The meta-analytic calculation was made with Comprehensive MetaAnalysis (V3) 
software using the random effects model (the DerSimonian-Laird method). We calculated a 
weighted standard difference in means and 95% CI. In the case of one study (Abu-El-Haija et 
al., 2016 (121)), we converted the median and range values to means and standard deviation 
using the modified Hozo’s formula by Wan et al., 2014 (125). For a visual inspection, we used 
a forest plot.  
 
 
Fig. 14. Two articles containing three separate data pairs. A) Collected parameters. B) Forest plot analyses on 
length of hospitalization (LOH). EEN=early enteral nutrition; NPO=nil per os; IVF=intravenous fluid; lo=low; 
hi=high; ICU=intensive care unit; AP=acute pancreatitis; PO=per os.  
 
IV.2.4. Results 
Fig. 14A shows the parameters collected from the articles. It was only possible to 
perform forest plot analyses on LOH (Fig. 14B). EEN significantly decreased LOH (SD= 
0.806, p = 0.034) compared to the standard NPO diet in case of APP. 
 
- 36 - 
 
IV.2.5. Discussion 
Several therapeutic recommendations are available in the literature on nutrition in AP. 
The IAP/APA guideline suggests enteral tube feeding as the first-line therapy in patients with 
predicted SAP, and oral feeding in the case of predicted mild AP (36). According to the 
Japanese guideline, enteral nutrition can decrease the incidence of complications and elevate 
the survival rate in the early phase of SAP (40). Recent meta-analysis of adult studies revealed 
that EEN decreases mortality, rate of interventions, and the incidence of MOF in SAP. 
Moreover, group analysis of 17 parameters including laboratory parameters (such as CRP and 
WBC) and symptoms (such as pain or presence of SIRS) suggested that EEN also has merits 
in mild AP (31).  
Since the incidence of APP has risen in the past twenty years (3.6 and 13.2 per 100,000 
children affected annually), we systematically reviewed the literature to understand whether 
there is any beneficial effect of EEN versus NPO therapy in children (44, 45). We faced several 
difficulties during our review: (i) APP is still underdiagnosed, thus decreasing the possibility 
of performing clinical trials; (ii) the number of studies on the management of these patients is 
very low, and there is still only a small number of studies focused on understanding the 
characteristics of the childhood onset disease (126); (iii) studies have not focused on the early 
management of the patients, therefore the groups were not separated; and finally, (iv) the 
quality of the methods sections and data presentation in these articles is very low. 
Consequently, in many cases it was impossible to obtain quality analyzable data from the 
articles for proper broad-spectrum meta-analysis. By the end of the search, we identified five 
articles containing relevant data on nutritional management during the early phase of APP. 
Raizner et al. (123) published a retrospective analysis involving seven children with 
necrotizing pancreatitis. All the children received a strict NPO diet for 1-11 days, five patients 
received TPN for 8-18 days, and just one patient was treated with nasojejunal feeding for 7 
days. All the children required intensive supportive treatment and a prolonged hospital stay 
(with a mean of 20 days) because of the complications. Goh et al (100) included twelve patients 
in their retrospective study. One patient needed a distal pancreatectomy, and eleven patients 
recovered with conservative management. Three patients received TPN, and eight patients 
were kept on bowel rest and nasogastric aspiration. Two patients had acute complications, and 
two patients had recurrent AP. Flores-Calderon et al (122) studied eighteen patients with AP 
caused by L-asparaginase due to acute lymphoblastic leukemia. All the patients were treated 
with bowel resting for a mean of 22 days (range: from 3-66 days), fourteen of the patients 
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received TPN, and four had an elementary diet. Two of the patients required ICU admission, 
and local complications developed in twelve patients. None of the patients died from 
complications related to AP. Although these studies point out several disadvantages of the NPO 
diet, none of them could be enrolled in our meta-analysis. Finally, it was possible to collect 
three sets of analyzable data pairs where both NPO and EEN were present. Abu-El-Haija et al 
(121) conducted a prospective study of 33 patients (38 admissions) suffering from mild AP, 
and retrospectively investigated the relationship of nutrition with abdominal pain and LOH. 
EEN feeding meant per os feeding, and NPO was identified as oral feeding not being allowed 
for 24 hours. Importantly, EEN, even with high fat intake, did not cause elevation in pain in 
children, suggesting that EEN is a well tolerable nutritional possibility in children. The fact 
that LOH was shorter in the EEN group versus the NPO group points to EEN as a better way 
of treating APP. The most advanced study was performed by Szabo et al (124), where several 
parameters were collected to understand the effect of EEN on the course of APP. A total of 201 
patients suffering from mild AP on admission were enrolled retrospectively. They compared 
EEN versus NPO both with and without aggressive fluid resuscitation. Fluid therapy was 
administered during the first 24 hours, and the type of nutrition was determined during the first 
48 hours. Besides the beneficial effects of EEN on LOH, they also showed that EEN reduced 
the severity of the disease and the rate of ICU transfer.  
Although our aim was to perform a meta-analysis on several parameters to understand 
the differences between EEN and NPO in childhood onset AP, we were only able to perform 
the statistical analysis on LOH, which suggested that EEN is not only a safe method of nutrition 
but also substantially decreases LOH, resulting in a better and less expensive treatment of APP 
(124). 
 
IV.3. CONCLUSION 
 
Based on our current knowledge, there are remarkable differences between childhood 
and adult onset AP (46). However, the majority of the current pediatric guidelines are adopted 
from adult data (37). Therefore, prospective observational and interventional pediatric clinical 
trials would be necessary to understand the differences between childhood and adult onset AP 
and to be able to provide appropriate patient care to children suffering from AP. However, most 
of the pediatric cohorts are limited as a result of the low incidence of AP and small sample size, 
which is particularly due to missing evidence-based diagnostic guidelines and lower awareness 
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of AP among pediatricians. Consequently, the HPSG aimed to solve this unmet need and 
established the PINEAPPLE study to estimate the real incidence of AP in children, and to 
create an evidence-based diagnostic guideline for APP. Additionally, not only diagnostic, but 
also therapeutic guidelines for childhood onset AP are based on adult data. EEN was proven to 
be beneficial for treating AP in adults compared to NPO and TPN therapy. Therefore, we aimed 
to collect all the relevant data on EEN in APP from the literature to achieve a higher level of 
evidence in childhood as well. Our meta-analysis suggests that EEN should have priority in 
treating APP compared to NPO therapy, and confirmed the necessity of further clinical trials 
in children.  
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V. SUMMARY AND NEW DISCOVERIES 
 
Chapter III: Dose-dependent effect of hypertriglyceridemia on acute pancreatitis 
1. Although we confirmed that biliary etiology is less common with HTG-AP, HTG-AP 
was associated with biliary etiology in 5.4%, but with alcoholic etiology in 38.2%. 
2. HTG was significantly and dose-dependently linked to younger age, male gender, 
obesity and pre-existing DM in AP patients. 
3. Amylase and lipase levels have shown a significant and dose-dependent reduction with 
the elevation of TG in AP. 
4. Our analysis has shown that local complications and organ failure were significantly 
and dose-dependently increased by HTG in AP. 
5. TG level above 11.3 mmol/l was associated with a significantly higher rate of 
moderately severe AP and longer hospital stay, whereas TG level above 22.6 mmol/l 
was significantly related to SAP as well. 
6. Our data suggest that lipid-lowering therapy may be important clinically at a much 
lower TG level in HTG-AP patients than we previously thought.  
 
Chapter IV: Children are not small adults 
 
The PINEAPPLE study will help to estimate the real incidence of AP in children and create 
evidence-based diagnostic guidelines for APP.  
Our meta-analysis: (i) proves that EEN shortens the LOH in the case of AP not only in adults, 
but also in children; (ii) suggests that EEN is safe and should have priority in treating APP 
compared to NPO therapy, and; (iii) confirms the necessity of further interventional clinical 
trials in children. 
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VI. CONTRIBUTION 
 
During my PhD work, we aimed to improve the clinical practice of AP in children and adults. 
This has allowed me to learn the clinical methodologies of study design, observational clinical 
trial, meta-analysis, and cohort analysis.  
 
VI.1. Mosztbacher et al. Pancreatology, 2020. 
I took part in the study design, data analysis and data interpretation, and I wrote the 
article with the contributions of Péter Hegyi and Andrea Párniczky. Furthermore, figures were 
created by myself and Lilla Hanák. I contributed to the patient involvement in the AP registry 
operated by the HPSG. 
 
VI.2. Mosztbacher et al. World J Gastroenterol, 2017. 
I contributed to the study design and data interpretation, and I wrote the article with the 
help of Péter Hegyi and Andrea Párniczky. Furthermore, figures were created by myself and 
Nelli Farkas. 
 
VI.3. Zsoldos et al. Digestion, 2016 
As the principle investigator of the study, I am responsible for making presentations at 
national and international conferences in order to involve as many centers as possible. In 
addition, I organize and maintain relations with the enrolled centers and provide the 
professional supervision of the study. I have enrolled 133 patients to the PINEAPPLE-P and 2 
centers to the PINEAPPLE-R studies. I am responsible for data control and data analysis of 
both subtrials. 
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Background: Hypertriglyceridemia is the third most common cause of acute pancreatitis (AP). It has been
shown that hypertriglyceridemia aggravates the severity and related complications of AP; however,
detailed analyses of large cohorts are contradictory. Our aim was to investigate the dose-dependent
effect of hypertriglyceridemia on AP.
Methods: AP patients over 18 years old who underwent triglyceride measurement within the initial
three days were included into our cohort analysis from a prospective international, multicenter AP
registry operated by the Hungarian Pancreatic Study Group. Data on 716 AP cases were analyzed. Six
groups were created based on the highest triglyceride level (<1.7 mmol/l, 1.7e2.19 mmol/l, 2.2
e5.59 mmol/l, 5.6e11.29 mmol/l, 11.3e22.59 mmol/l, 22.6 mmol/l).
Results: Hypertriglyceridemia (1.7 mmol/l) presented in 30.6% of the patients and was significantly and
dose-dependently associated with younger age and male gender. In 7.7% of AP cases, hyper-
triglyceridemia was considered as a causative etiological factor (11.3 mmol/l); however, 43.6% of these
cases were associated with other etiologies (alcohol and biliary). Hypertriglyceridemia was significantly
and dose-dependently related to obesity and diabetes. The rates of local complications and organ failure
and maximum CRP level were significantly and dose-dependently raised by hypertriglyceridemia. Tri-
glyceride above 11.3 mmol/l was linked to a significantly higher incidence of moderately severe AP and
longer hospital stay, whereas triglyceride over 22.6 mmol/l was significantly associated with severe AP as
well.
Conclusion: Hypertriglyceridemia dose-dependently aggravates the severity and related complications of
AP. Diagnostic workup for hypertriglyceridemia requires better awareness regardless of the etiology of
AP.
© 2020 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Hypertriglyceridemia (HTG) affects 10e30% of the general adult
population [1,2]. Classifying HTG is complex; both genetic (pri-
mary) and environmental (secondary) factors can lead to an
elevated triglyceride (TG) level. In rare cases (2%), primary severe
HTG (TG  10 mmol/l) may arise as a result of autosomal recessive,
monogenic familial chylomicronemia syndrome (FCS, former Type
I). However, a majority of severe HTG cases are multifactorial and
have polygenic (mixed HTG, former Type V) determinants with
additional secondary factors. Mild-to-moderate HTG cases
(2e9.9 mmol/l TG) are similarly polygenic with complex genetic
susceptibility (former Type IV, Type IIB and Type III) [2e4]. As
regards environmental factors, alcohol, positive-energy balanced
diet, obesity, uncontrolled diabetes mellitus (DM), renal diseases,
pregnancy, hypothyroidism and medications (e.g., estrogen, reti-
noids, thiazides, and b-blockers) were shown to be responsible for a
raised TG level usually with the interaction of genetic susceptibility
[5,6].
HTG is the third most common cause of acute pancreatitis (AP),
and it is responsible for up to 15% of AP cases [7e9]. According to
the definition, the majority of experts agree that AP related to TG
above 5.6 mmol/l should be considered as suspected
hypertriglyceridemia-induced acute pancreatitis (HTG-AP) and AP
associated with TG over 11.3 mmol/l is confirmed as HTG-AP [4,10].
Importantly, the occurrence of AP increases with the increase in TG
level. There is a 5% possibility of developing AP if TG exceeds
11.3 mmol/l, and it rises to 10e20% if TG elevates over 22.6 mmol/l
[4]. HTG-AP is of great importance for several reasons: 1) it has
shown a rising incidence worldwide as a result of increasing
obesity-related dyslipidemia [11,12]; 2) it raises the risk of severe
AP and related complications [8,10,12e16]; and 3) there is no
evidence-based therapy for it [17e19].
We aimed to perform a cohort analysis for investigating the
dose-dependent effect of HTG on AP and providing data for further
prospective randomized clinical trials. In our current cohort study,
we show clear evidence that TG level dose-dependently worsens
the outcome of AP. The rate of local complications is significantlyhigher above 5.6 mmol/l, whereas significantly elevated organ
failure presents above 11.3 mmol/l TG level, strongly suggesting
that TG-lowering therapy can achieve a better outcome of AP at a
much lower TG level than we previously thought.
Methods
AP patients (n ¼ 1435) over 18 years old were enrolled in the
prospectively collected international, multicenter AP registry
operated by the Hungarian Pancreatic Study Group (HPSG) be-
tween 2012 and 2017. Post-hoc cohort analysis was performed on
716 AP cases who underwent TG measurement within 72 h from
admission. AP was diagnosed based on the International Associa-
tion of Pancreatology/American Pancreatic Association (IAP/APA)
and HPSG evidence-based guidelines [17,18]. Participating coun-
tries are shown in Sup. Fig. 1.
The threshold of the normal TG value was determined at
1.7 mmol/l [6]. Six groups were established based on the Endocrine
Society Clinical Practice Guideline and previously published clinical
data related to HTG-AP [4,6]: Group 1: <1.7 mmol/l; Group 2:
1.7e2.19 mmol/l; Group 3: 2.2e5.59 mmol/l; Group 4:
5.6e11.29 mmol/l; Group 5: 11.3e22.59 mmol/l; and Group 6:
22.6 mmol/l. To convert TG from mmol/l to mg/dl multiply by
88.57. In case of each variable, elevated TG groups (Groups 2e6)
were compared with the normal TG group (Group 1). TG categories
were collapsed to three groups (<1.7 mmol/l; 1.7e11.29 mmol/l;
11.3 mmol/l) for the analysis of organ failure because of the low
event number.
Seventy-three variables were collected from each AP case as
listed in Table S1. The analysis was performed on 42,655/52,268
available data. Local complications, organ failure and severity were
defined based on the revised Atlanta classification [20]. The 716
cases investigated have shown the same epidemiological andmajor
outcome distribution as the total cohort (1435 cases), demon-
strating that our patients’ population represents a normal AP
cohort (Sup. Fig. 2).
The registry received ethical permission from the Scientific and
Research Ethics Committee of the Medical Research Council
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616610(22254e1/2012/EKU) in 2012, and all the patients provided written
informed consent to participate. The study protocol conforms to the
ethical guidelines of the Declaration of Helsinki updated in 2013 as
reflected in a priori approval by the institution’s human research
committee.
Statistical analysis
Prior to analysis of the dataset, descriptive statistical tools were
used to describe the basic characteristics. Mean and standard error
of the mean were calculated for continuous variables, whereas the
incidence in each group was determined for categorical variables.
Depending on the distribution of the data, the independent Stu-
dent’s t-test or ManneWhitney U test was used to evaluate dif-
ferences between continuous parameters. The chi-square test or
Fisher’s exact test was conducted to analyze the relations between
the variables. We compared the confidence intervals (CI) of the
proportions to investigate differences in the incidence of moder-
ately severe cases between groups. A p-value less than 0.05 (0.05)
was determined as statistically significance. All analyses were
performed using IBM-SPSS Statistical Software Version 25 (IBM
Corporation, Armonk, NY, USA).
Results
In our cohort, 30.6% (n ¼ 219) of the patients presented withFig. 1. Epidemiology and etiology. A) Age distribution of acute pancreatitis (AP) cases in m
p ¼ 0.010). C) Gender distribution of triglyceride groups (e: p ¼ 0.002; f, g: p <
cholangiopancreatography.elevated TG level (1.7 mmol/l). HTG was significantly and dose-
dependently linked to younger age and male gender (Fig. 1AeC).
In 7.7% of AP cases (n ¼ 55), TG level was above 11.3 mmol/l, which
is considered as a causative etiological factor [6,10]. In 56.4% of
these cases, HTG-AP patients had no other etiology described;
however, raised TG level was also accompanied by alcohol in 38.2%
of these cases and by biliary etiology in 5.4%, showing that HTG-AP
is associated with other etiologies in a substantial number of cases
(Fig. 1D).
Data from patients’ medical history revealed that HTG is
significantly and dose-dependently linked to obesity and DM
(Fig. 2B and C); however, there is no relation to chronic pancreatitis
(CP) and the Charlson comorbidity index (CCI) [21] (Fig. 2A and D).
The amount of previous AP in the medical history was higher in the
HTG group compared to the normal TG group (Fig. 2A). General
symptoms of AP and physical examination on admission (inci-
dence, duration and intensity of pain, nausea, vomiting, abdominal
tenderness and guarding, and blood pressure) have not shown a
significant link to elevated TG level (Fig. 3A and B). However, HTG
was significantly related to increased heart rate (Fig. 3C). As regards
the laboratory parameters on admission showing significant dif-
ferences with HTG, amylase, lipase, sodium, and calcium were
associated inversely; however, glucose, C-reactive protein (CRP),
cholesterol, red blood cell count (RBC), hemoglobin, and hematocrit
were related parallel with TG level (Fig. 4). On admission laboratory
parameters consistent with cholestasis suggested that HTG is lessales and females. B) Age distribution of triglyceride (TG) groups (a, c, d: p¼<0.001; b:
0.001). D) Etiology. HTG ¼ hypertriglyceridemia; ERCP ¼ endoscopic retrograde
Fig. 2. Medical history of triglyceride groups. A) Acute pancreatitis (AP) and chronic pancreatitis (CP) in patients’ medical history (a: p ¼ 0.026; b: p ¼ 0.023). B) Obesity (body
mass index (BMI), kg/m2) (c: p ¼ 0.006; d: p ¼ 0.001). C) Diabetes mellitus in medical history (e: p ¼ 0.046; f: p ¼ 0.016; g: p ¼ 0.026; h: p < 0.001). D) Charlson comorbidity index
(CCI). N numbers (n) indicate the total number of cases in each triglyceride group.
Fig. 3. Symptoms and physical findings on admission in the different triglyceride (TG) groups. A) Incidence, duration before admission and intensity of pain. Nausea, vomiting,
abdominal tenderness and abdominal guarding (a: p ¼ 0.025; b: p ¼ 0.036). B) Systolic and diastolic blood pressures (Hgmm) (c: p ¼ 0.012). C) Heart rate (bpm) (d, e: p ¼ 0.010). N
numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 611common in cases with biliary etiology. (Sup. Fig. 3). The parallel rise
in gamma-glutamyltransferase (gGT) and TG levels confirms that
alcohol consumption is linked to HTG (Sup. Fig. 3D). White bloodcell count (WBC), thrombocyte, lactate dehydrogenase (LDH), blood
urea nitrogen (BUN), creatinine, and potassium had no significant
relation to HTG (Sup. Fig. 4).
Fig. 4. Laboratory parameters on admission significantly associated with hypertriglyceridemia. A) Triglyceride groups [1e6]. B) Amylase (U/l) (a: p ¼ 0.036; b, c, e: p¼<0.001;
d: p ¼ 0.009). C) Lipase (U/l) (f: p ¼ 0.017; g: p ¼ 0.001). D) Sodium (mmol/l) (h, i: p¼<0.001; j: p ¼ 0.005). E) Calcium (mmol/l) (k: p ¼ 0.012). F) Glucose (mmol/l) (l, m: p¼<0.001).
G) C-reactive protein (CRP, mg/l) (n: p ¼ 0.021; o: p ¼ 0.014). H) Cholesterol (mmol/l) (p: p ¼ 0.008; q: p ¼ 0.006; r, s: p < 0.001). I) Red blood cell count (RBC, T/l) (t: p ¼ 0.017; u:
p ¼ 0.004) J) Hemoglobin (G/l) (v: p ¼ 0.008; w: p < 0.001; x: p ¼ 0.002). K) Hematocrit (%) (y: p ¼ 0.009; z: p ¼ 0.014). N numbers (n) indicate the total number of cases in each
triglyceride group.
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D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 613The rate of local complications, including peripancreatic fluid
collection, pancreatic necrosis and DM, was significantly and dose-
dependently increased with TG level (Fig. 5BeE); however,
pancreatic pseudocysts did not show significant differences be-
tween the investigated groups above 2.2 mmol/l (Fig. 5F). Organ
failure, including heart and renal failure, and maximum CRP level
were significantly and dose-dependently raised by TG level (Fig. 6B,
D-G); however maximum WBC has not shown any significant dif-
ferences by HTG (Fig. 6C).
As regards severity, TG level above 11.3 mmol/l was associated
with a significantly higher rate of moderately severe AP and longer
hospital stay, whereas TG level above 22.6 mmol/l was significantly
related to severe AP as well (Fig. 7A and B). Due to the low event
rate, the effect of HTG on mortality could not be determined
(Fig. 7A). Detailed values of charts and statistical parameters are
shown in Tables S2 and S3.
Plasmapheresis was carried out in 36.4% (20/55) of the HTG-AP
cases; 85% of these patients had an initial TG level higher than
22.6 mmol/l and the average TG level was 70.1 ± 10.0 mmol/l.
Discussion
HTG-AP has grown in incidence and importance. According to
the previously published literature [7,9], HTG is the third most
common cause of AP (7.7%). However, it seemsmore than likely that
the incidence of HTG-AP is higher than is usually recorded. The
prospective multicenter, international AP cohort run by the HPSG
revealed that TG measurement is performed in just 50% (716/1435)
of AP cases within the first three days from admission and most
probably this rate is even worse in centers which provide no data.
Furthermore, our data also confirmed additional etiological factors
(alcohol and biliary disease) besides HTG in 43.6% of HTG-AP cases
and showed a dose-dependent relation between obesity (body
mass index), pre-existing DM and HTG. These data also suggest a
higher incidence rate since physicians finding an etiological factor
behind AP usually stop further investigation. Our data are in
accordance with Scherer et al. who recommend that HTG-AP
should be suspected in the case of significant alcoholFig. 5. Local pancreatic complications in the different triglyceride groups. A) Triglyceride
collection (c: p ¼ 0.004; d: p < 0.001). D) Pancreatic necrosis (e: p ¼ 0.003; f: p < 0.001). E) D
pseudocyst (j: p ¼ 0.031). N numbers (n) indicate the total number of cases in each triglycconsumption, poorly controlled DM and metabolic syndrome,
including obesity [4]. Although our data clearly show that biliary
obstruction may be associated with HTG, serum TG was measured
in just 44.3% (266/601) of the biliary AP cases. Furthermore, in the
case of biliary AP, there is no recommendation for TGmeasurement.
Our data analysis confirmed results published by Zheng et al.
[12] and Zhu et al. [8] which show that HTG is significantly linked to
younger age and male gender. This is not surprising, since under-
lying genetic abnormalities behind HTG contribute to younger
manifestation and alcohol-related HTG affects male gender and
younger age more [3,4,22]. In contrast, biliary etiology is accom-
panied by a higher rate for female gender and older population
[3,23].
Diagnosing AP in the presence of HTG can be challenging due to
in vitro interference between plasma TG level above 5.6 mmol/l
(with grossly turbid plasma) and determination of amylase and
lipase activities [24,25]. Our data confirmed a significant reduction
of amylase and lipase levels with the elevation of TG. Furthermore,
case reports have been published by Singh et al. [26] and Sotello
et al. [27], presenting HTG-AP patients with normal amylase and
lipase levels.
Our analysis has shown that local complications and organ
failure were significantly increased by HTG, just as published in
previous reports and a recent meta-analysis by Kiss et al.
[10,13,15,28,29]. Nawaz et al. [30] confirmed that TG above
2.3 mmol/l is independently associated with persistent organ fail-
ure on a multivariate analysis controlling for age, gender, body
mass index, diabetes, and alcohol etiology, whereas Szentesi et al.
[31] revealed that hyperlipidemia was an independent predictive
factor for local complications and new-onset DM. Although we
could not confirm a significantly higher risk of pancreatic pseu-
docysts in the case of TG above 2.2 mmol/l, it is well known that
pseudocysts usually occur more than four weeks after the onset of
AP and the average hospital stay was 10.4 ± 0.3 days in our cohort
[20].
Based on our data analysis, severity of AP and length of hospi-
talizationwere significantly increased by HTG [8,10,12,13,29,30,32].
Navarro et al. [33] and Goyal et al. [34] also confirmed that HTGgroups [1e6]. B) Local pancreatic complications (a, b: p < 0.001). C) Peripancreatic fluid
iabetes mellitus as complication (g: p ¼ 0.004; h: p < 0.001; i: p ¼ 0.011). F) Pancreatic
eride group.
Fig. 6. Systemic inflammatory effect and organ failure in the different triglyceride groups. A) Triglyceride groups [1e6]. B) Maximum C-reactive protein (Max CRP, mg/l) (a, c:
p < 0.001; b: p ¼ 0.029). C)Maximumwhite blood cell count (Max WBC, G/l). D) Organ failure (d: p ¼ 0.001). E) Respiratory failure. F) Heart failure (e: p ¼ 0.007). G) Renal failure (f:
p ¼ 0.002). N numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616614aggravates the severity of AP compared to biliary and alcoholic
etiology, respectively. The underlying mechanism is clearly com-
plex. Unsaturated free fatty acids (UFAs) generated from TG areresponsible for cell injury by membrane lipid peroxidation, long-
lasting cytosolic Ca2þ elevation and mitochondrial damage
[35,36]. In the case of additional alcohol consumption, non-
Fig. 7. Outcomes in the different triglyceride (TG) groups. A) Length of hospitalization (LOH, day) and mortality (event n) (a: p ¼ 0.034; b: p ¼ 0.001). B) Severity (c: p ¼ 0.001; d:
p < 0.001). Moderately severe acute pancreatitis (AP) cases (Group 1: 22.6% (95% CI: 19%e26.6%); Group 5: 66.7% (95% CI: 38.4%e88.2%); Group 6: 47.4% (95% CI: 31.0%e64.2%)).
Severe AP cases (e: p ¼ 0.006). N numbers (n) indicate the total number of cases in each triglyceride group.
D. Mosztbacher et al. / Pancreatology 20 (2020) 608e616 615oxidative ethanol metabolites (fatty acid ethyl esters, FAEEs)
contribute to the persistent Ca2þ elevation and drop of ATP level
[37,38]. Besides, the raised plasma viscosity caused by hyper-
chylomicronemia leads to ischemia and acidosis in the pancreatic
capillaries [5]. This pathologic environment results in an early
trypsinogen activation and pancreatic lipase leakage, leading to
further free fatty acid (FFA) release and accumulation [5,35,39].
Moreover, UFAs bring about a systemic pro-inflammation by
increased mRNA production of tumor necrosis factor-alpha (TNF-a)
and neutrophil chemoattractants, thereby increasing the severity of
AP [36]. In our cohort, heart rate and maximum CRP were signifi-
cantly raised by HTG, confirming the systemic inflammatory effect
of relatively high TG level. In contrast, Pothoulakis et al. [40] and
Balachandra et al. [41] reported that HTG does not worsen severity.
Furthermore, Wang et al. showed that longer hospital stay was
associated with higher TG level, but the difference was not signif-
icant [29].
The overall mortality of AP is ~1% based on the literature [3,12]
and 1.5% in our cohort, but we could not perform a further sub-
group analysis because of the low event number. Zhu et al. [8] and
Deng et al. [42] confirmed that HTG-AP is accompanied by a
significantly higher rate of mortality among severe AP cases
compared to biliary AP and non-HTG etiology, respectively. How-
ever, Tai et al. [32] showed that mortality was similar in HTG-AP
and biliary AP groups in a general AP cohort.
In our cohort, plasmapheresis was carried out in 36.4% of the
HTG-AP cases. Although our data clearly suggest that the severity of
AP is significantly elevated above 11.3 mmol/l TG level, the average
TG level was 70.1 ± 10.0 mmol/l in patients with plasmapheresis
and 85% of these cases had a TG level over 22.6 mmol/l. We could
not state any further conclusion regarding the therapy because of
incomplete data and lack of randomization as a result of the cohort
feature of the dataset. Overall, in most cases, TG-lowering therapy,
such as plasmapheresis and glucose-heparin-insulin (GLU-HEP-
INS) administration, is performed above a TG level of 40 mmol/l. In
order to solve this unmet need, the HPSG has initiated a prospective
randomized clinical trial to investigate different lipid-lowering
therapies in AP [43].
Our study has several limitations. Although all data were
collected prospectively, all questions were raised retrospectively.
Cases were included into the analysis with TGmeasurement within
the first three days from admission, but unfortunately still just 50%
of the entire cohort met the inclusion criteria. We attempted to
minimize these limitations by comparing the epidemiological and
major outcome distributions of the data analyzed and the whole
cohort. We confirmed that the population under investigationrepresents a normal AP cohort.
Conclusion
Our results confirm that HTG dose-dependently increases the
complications and severity of AP and highlights the necessity of
better awareness of an accurate determination of causative and
influencing risk factors in AP regardless of the etiology. Our data
suggest that lipid-lowering therapymay be important clinically at a
much lower TG level than we previously thought.
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Abstract
Acute pancreatitis (AP) is a serious inflammatory 
disease with rising incidence both in the adult and 
pediatric populations. It has been shown that mitoc-
hondrial injury and energy depletion are the earliest 
intracellular events in the early phase of AP. Moreover, 
it has been revealed that restoration of intracellular 
ATP level restores cellular functions and defends 
the cells from death. We have recently shown in a 
systematic review and meta-analysis that early enteral 
feeding is beneficial in adults; however, no reviews are 
available concerning the effect of early enteral feeding 
in pediatric AP. In this minireview, our aim was to 
systematically analyse the literature on the treatment 
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MINIREVIEWS
Restoration of energy level in the early phase of acute 
pediatric pancreatitis
Dóra Mosztbacher, Nelli Farkas, Margit Solymár, Gabriella Pár, Judit Bajor, Ákos Szűcs, József Czimmer, 
Katalin Márta, Alexandra Mikó, Zoltán Rumbus, Péter Varjú, Péter Hegyi, Andrea Párniczky
of acute pediatric pancreatitis. The preferred reporting 
items for systematic review (PRISMA-P) were followed, 
and the question was drafted based on participants, 
intervention, comparison and outcomes: P: patients 
under the age of twenty-one suffering from acute 
pancreatitis; I: early enteral nutrition (per os and 
nasogastric- or nasojejunal tube started within 48 h); 
C: nil per os therapy; O: length of hospitalization, need 
for treatment at an intensive care unit, development 
of severe AP, lung injury (including lung oedema and 
pleural effusion), white blood cell count and pain score 
on admission. Altogether, 632 articles (PubMed: 131; 
EMBASE: 501) were found. After detailed screening 
of eligible papers, five of them met inclusion criteria. 
Only retrospective clinical trials were available. Due to 
insufficient information from the authors, it was only 
possible to address length of hospitalization as an 
outcome of the study. Our mini-meta-analysis showed 
that early enteral nutrition significantly (SD = 0.806, P  
= 0.034) decreases length of hospitalization compared 
with nil per os diet in acute pediatric pancreatitis. In 
this minireview, we clearly show that early enteral 
nutrition, started within 24-48 h, is beneficial in acute 
pediatric pancreatitis. Prospective studies and better 
presentation of research are crucially needed to achieve 
a higher level of evidence.
Key words: Pediatric pancreatitis; Enteral nutrition; Nil 
per os diet; ATP restoration; length of hospitalization
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Acute pancreatitis is a serious inflammatory 
disease with rising incidence both in adult and pediatric 
medicine. Despite the existing research activities in 
this field, no specific therapy is available to treat this 
disease. Results in basic science strongly suggest 
that early energy restoration could be the first-line 
treatment for acute pancreatitis. Our minireview 
suggests that early enteral nutrition should have 
priority in the treatment of acute pediatric pancreatitis.
Mosztbacher D, Farkas N, Solymár M, Pár G, Bajor J, Szűcs 
Á, Czimmer J, Márta K, Mikó A, Rumbus Z, Varjú P, Hegyi 
P, Párniczky A. Restoration of energy level in the early phase 
of acute pediatric pancreatitis. World J Gastroenterol 2017; 
23(6): 957-963  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i6/957.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i6.957
INTRODUCTION
Acute pancreatitis (AP) is a serious inflammatory dis­
ease with rising incidence both in adult and pediatric 
populations[1,2]. Common characteristics in both age 
groups are that no specific therapy is available to 
treat the disease and that the general supportive treat­
ments at the early phase of the disease are usually 
volume resuscitation and a nil per os (NPO) diet[3­6]. 
However, while there is clear evidence in the literature 
that volume therapy is beneficial, the latter treatment 
is questionable.
One of the main reasons for the debate is that 
the pathogenesis of the disease clearly suggests the 
opposite. Irrespective of the etiological factors, mito­
chondrial damage and energy depletion are the 
leading intracellular responses in the early phase of the 
disease in the exocrine pancreas[7­10]. Bile acids[11­14], 
ethanol, fatty acids and their non­oxidative metab­
olites, fatty acid ethyl esthers[8,9,15­18] were shown to 
elevate the intracellular Ca2+ concentration, caus­
ing mitochondrial damage and a resultant decrease 
of intracellular ATP concentration. This will lead to 
inhibited fluid and bicarbonate secretion and CFTR Cl­ 
channel dysfunction in the ductal cells and secretory 
block and intracellular trypsinogen activation in the 
acinar cells (Figure 1)[9,16,19,20]. Very importantly, res­
toration of ATP levels both in acinar and ductal cells 
prevents (at least in part) the toxic effects of the etio­
logical factors[7,21,22] noted above. These data strongly 
suggest that an energy supply, for example, via enteral 
nutrition, should be beneficial for patients as compared 
to nil energy.
Notably, early enteral nutrition (EEN) either via 
oral, nasogastric­ or nasojejunal tube feeding is ben­
eficial as regards systemic infections, complications, 
multi­organ failure, need for surgical interventions 
and mortality[6,23­30]. Enteral nutrition has already been 
proven to be beneficial in other inflammatory gastroin­
testinal diseases. The first­line recommendation to 
induce remission in pediatric Crohn’s disease is exclu­
sive enteral nutrition[31]. Enteral nutrition could also 
be effective in the maintenance of pediatric inflam­
matory bowel disease remission[32]. With regard to 
acute pancreatitis, three of the recent and most up­to­
date guidelines for acute pancreatitis in adults clearly 
show the positive effect of enteral nutrition in moder­
ate and severe AP[6,23,24]. Besides the energy supply, 
enteral nutrition in patients can also have other advan­
tages as a first­line treatment for patients. It is well 
documented that the gut plays an important role as 
an immune barrier in the immune system and that 
EEN facilitates this barrier function. EEN significantly 
decreases pathogenic bacteria in the stool, altera­
tion of intestinal flora and levels of serum endotoxins. 
EEN has a favourable effect on immune dysregulation 
caused by severe acute pancreatitis, which can reduce 
APACHE II scores, pancreatic sepsis, initial incidences 
of systemic inflammatory response syndrome (SIRS) 
and multiple organ dysfunction syndrome[33,34].
Recent meta­analyses of adult data showed that 
EEN is beneficial in all severity groups in AP; however, 
no systematic review is available concerning the role of 
EEN in pediatrics[35]. Therefore, the aim was to review 
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Table 1  Studies included in the quantitative synthesis
EEN: Early enteral nutrition; NPO: Nil per os.
the literature to analyse the effect of EEN vs NPO 
therapy on the outcome of acute pediatric pancreatitis 
(APP) and aggregate the information in APP leading 
to a higher statistical power and more robust point 
estimate than is possible from the individual studies.
The preferred reporting items for systematic 
review and meta­analysis protocol (PRISMA­P) were 
followed[36]. Our structured literature search was 
based on the participants, intervention, comparison 
and outcomes format: P: patients under the age of 
twenty­one suffering from acute pancreatitis; I: early 
enteral nutrition (per os and nasogastric­ or nasoje­
junal tube started within 48 h); C: NPO therapy [per 
os/nasogastric­ or enteral tube after 48 h and total 
parenteral nutrition (TPN) within or after 48 h]; O: 
length of hospitalization, need for intensive care unit 
(ICU), complications, necessity of antibiotics, surgi­
cal/non­surgical interventions and mortality.
In February 2016, a literature search was per­
formed on the PubMed (http://www.ncbi.nlm.nih.
gov/pubmed) and EMBASE (https://www.embase.
com) databases using the following Medical Subject 
Headings and search terms: “pediatric” OR “paediatric” 
AND “pancreatitis”. The search was limited to human 
studies, full­text publications with abstracts in English 
with no time period, resulting in 632 articles altogether 
(PubMed: 131; EMBASE: 501).
The articles were checked separately. Meta­analyses, 
reviews, case reports and articles on chronic pancreati­
tis were excluded and duplicates were removed (Figure 
2). Potentially eligible papers were selected, and, 
finally, five of them with relevant data on EEN or/with 
NPO therapy in acute pediatric pancreatitis in patients 
under twenty­one years old were included (Table 
1)[37­41]. To reduce the risk of bias, the literature search 
was independently performed by three researchers 
following the inclusion criteria noted above.
The details in the collected articles were checked, 
and only articles where both EEN and NPO were 
presented separately were used. Two articles met this 
criterion. The two articles contained three separate 
data pairs, where EEN was compared to NPO (Figure 
3). The following parameters were collected: length of 
hospitalization (LOH), need for treatment at an ICU, 
development of severe AP, lung injury (including lung 
oedema and pleural effusion), white blood cell count 
and pain score on admission. Only one of the five 
investigated parameters (LOH) contained a minimum 
of three items, which were analysed statistically.
The meta­analytic calculation was made with 
Comprehensive MetaAnalysis (V3) software using 
the random effects model (the DerSimonian­Laird 
method). We calculated a weighted standard difference 
in means and 95%CI. In the case of one study (Abu­
El­Haija et al[37], 2016), we converted the median and 
range values to means and standard deviation using 
the modified Hozo’s formula by Wan et al[42]. For a 
visual inspection, we used a forest plot.
Figure 3 shows the parameters collected from the 
articles. It was only possible to perform forest plot 
analyses on LOH. EEN significantly decreased LOH (SD 
= 0.806, p = 0.034) compared to the standard NPO 
diet (Figure 3).
DISCUSSION
Several therapeutic recommendations are available 
in the literature on nutrition in acute pancreatitis. The 
IAP/APA guideline suggests enteral tube feeding as 
the first­line therapy in patients requiring nutritional 
support with predicted severe and severe acute pan­
creatitis[6]. According to the Japanese guideline, enteral 
nutrition in the early phase of severe acute pancreatitis 
can decrease the incidence of complications and ele­
vate the survival rate[24]. Recent meta­analyses of adult 
studies revealed that EEN decreases mortality, rate of 
interventions and the incidence of multi­organ failure 
in severe acute pancreatitis. Moreover, group analyses 
of 17 parameters including laboratory parameters 
(such as CRP and white blood cells) and symptoms 
(such as pain or presence of SIRS) suggested that EEN 
also has merits in mild acute pancreatitis. Since the 
incidence of APP has risen in the past twenty years (with 
3.6 and 13.2/100000 children affected annually), we 
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Ref. Data Groups NO. of patients
Abu-El-Haija et al[37], 2016 Yes EEN 24
NPO 14
Flores-Calderón et al[41], 2009 Only NPO 18
Goh et al[40], 2003 Only NPO 12
Raizner et al[39], 2013 Only NPO   7
Szabo et al[38], 2015 Yes EEN + IVF lo 55
NPO + IVF lo 20
Yes EEN + IVF hi 96
NPO + IVF hi 30
Figure 1  Early events in acute pancreatitis. Bile acids, ethanol, fatty 
acids or their non-oxidative metabolites, fatty acid ethyl esthers, induce 
calcium overload, causing mitochondrial damage and a resultant decrease in 
intracellular ATP concentration both in acinar and ductal cells. This will lead to 
general energy depletion in the pancreas.
Energy depletion
Ductal cells
Ca2+
Ca2+
Ca2+ overload
Mitochondrial injury
Acinar cells
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systematically reviewed the literature to understand 
whether there is any beneficial effect of EEN vs NPO in 
children[43,44].
We faced several difficulties during our review: (1) 
APP is still underdiagnosed, thus decreasing the pos­
sibility of performing clinical trials[45]; (2) the number 
of studies on the management of these patients is 
very low, and there is still only a small number of 
studies focused on understanding the characteristics 
of the disease[46]; (3) the studies have not focused 
on the early management of the patients; the groups 
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were therefore not separated; and (4) finally, but very 
importantly, the methods sections and the quality 
of data presentation in these articles are very low. 
Consequently, in many cases, it was impossible to 
obtain quality analysable data from the manuscripts 
for a proper broad­spectrum meta­analysis[37­39].
By the end of the search, we identified five articles 
containing relevant data on nutritional management 
during the early phase of APP. Raizner et al[39] published 
a retrospective analysis involving seven children with 
necrotizing pancreatitis. All the children received a 
Figure 2  Flow chart on the methods used in the literature search.
Records identified through database search
Pubmed n = 131
Embase n = 501
Records screened based on titles and 
abstracts 
n = 632
Full-text articles assessed for 
eligibility 
n  = 61
Studies included in quantitative synthesis
n  = 5
Records excluded n  = 571
(meta-analyses, case reports, reviews, 
chronic pancreatitis)
Records excluded n  = 56
(duplicates, adult data, no relevant data 
on enteral nutrition or nil per os diet)
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Figure 3  Two articles contained three separate data pairs where early enteral nutrition was compared to nil per os. LOH: Length of hospitalization; EEN: Early 
enteral nutrition; NPO: Nil per os. ICU: Intensive care unit; AP: Acute pancreatitis; WBC: White blood cell count.
Ref. Therapy n LOH Need for ICU Severe AP Lung 
injury
WBC Pain score
Abu-El-Haija 
et al [37], 2016
1 EEN (< 24 h) 24 81.7 h
NPO (< 24 h) 14 94.7 h
Szabo et al [38], 
2015
2 NPO (< 48 h) + IVF lo (< 24 h) 20 7.1 d (1.01 SE) 20.0% (8.94 SE) 35.0% (10.7 SE) 11 13.60 (6.44 SD) 4.95 (3.75 SD)
EEN (< 48 h) + IVF lo (< 24 h) 55 2.8 d (0.24 SE)   1.8% (1.80 SE)   9.1% (3.88 SE) 21   9.89 (3.89 SD) 4.62 (3.50 SD)
3 NPO (< 48 h) + IVF hi (< 24 h) 30 5.0 d (0.58 SE) 13.0% (6.21 SE) 17.0% (6.80 SE) 14 13.30 (4.76 SD) 6.08 (3.19 SD)
EEN (< 48 h) + IVF hi (< 24 h) 96 3.2 d (0.22 SE)   1.0% (1.04 SE)   4.2% (2.04 SE)   4 11.30 (5.25 SD) 5.47 (3.57 SD)
Study name Statistics for each study
Std diff 
in means
Standard 
error
Lower 
limit
Upper 
limit
Z value P value
Abu-El-Haija et al [37], 2016 0.089 0.336 -0.570 0.749 0.266 0.790
Szabo et al [38], 2015 A 1.554 0.290  0.985 2.122 5.352 0.000
Szabo et al [38], 2015 B 0.739 0.214  0.319 1.159 3.447 0.001
0.806 0.380  0.062 1.551 2.124 0.034
Std diff in means and 95%CI
-2.50            1.25            0.00            1.25           2.50
PO                               NPO
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strict NPO diet, five patients received TPN and just one 
patient was treated with nasojejunal feeding for seven 
days. All the children required a prolonged hospital stay 
(with a mean of 20 d) for acute complications, with 
three of them suffering from late complications[39]. Goh 
et al[40] included twelve patients in their retrospective 
study. One patient needed a distal pancreatectomy, 
and eleven patients recovered with conservative 
management, with none of them receiving EEN. Two 
patients had acute complications, and two patients 
had recurrent AP[40]. Flores­Calderon et al[41] studied 
eighteen patients with acute pancreatitis caused by 
L­asparaginase due to acute lymphoblastic leukemia. All 
the patients were treated with bowel resting for a mean 
of 22 d, fourteen of the patients received TPN and four 
had an elementary diet. Two of the patients required 
intensive care unit admission, with local complications 
developing in twelve patients. None of the patients died 
from complications related to AP. Although these stud­
ies point out several disadvantages of that NPO diet, 
none of them could be enrolled in our meta­analysis.
Finally, it was possible to collect three sets of 
analysable data pairs where both NPO and EEN were 
present. Abu­El­Haija et al[37] conducted a prospective 
study of 38 children suffering from mild AP and retro­
spectively investigated the relationship of nutrition with 
pain and LOS. EEN feeding meant per os feeding and 
NPO was identified as oral feeding not being allowed 
for 24 h. Importantly, EEN, even with high fat intake, 
did not cause an elevation in pain in children, suggest­
ing that EEN is a well tolerable nutritional possibility in 
children. The fact that LOS was much shorter in group 
EEN vs NPO points to EEN as a better way of treating 
APP[37]. The most advanced study was performed by 
Szabo et al[38], where several parameters were col­
lected to understand the effect of EEN on the course of 
APP. Two hundred and one children suffering from mild 
AP were enrolled retrospectively. They compared EEN 
vs NPO both with and without aggressive fluid resusci­
tation. Fluid therapy was administered during the first 
24 h, and the type of nutrition was determined during 
the first 48 h. Besides the beneficial effects of EEN on 
LOS, they also showed that EEN reduces the severity 
of the disease. Although our aim was to perform a 
meta­analysis on several parameters to understand 
the differences between EEN and NPO, we were only 
able to perform the statistical analyses on LOS, which 
clearly showed that EEN is not only a safe method of 
nutrition but also substantially decreases LOS, result­
ing in a better and less expensive treatment of mild 
APP[38].
CONCLUSION
The information collected by basic scientists, retro­
spective clinical studies and meta­analyses suggests 
that EEN should have priority in treating APP. However, 
it is perhaps self­evident that randomized multicenter 
clinical intervention trials would be crucial to achieving 
a higher level of evidence.
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reason behind this is the large differences that exist between 
the local managements of abdominal pain at emergency 
units. Unfortunately, no evidence-based medicine (EBM) 
guidelines are available to give proper instruction concern-
ing the necessity of serum pancreatic enzyme measurement 
during abdominal pain.  Summary: Pain in Early Phase of 
 Pediatric Pancreatitis (PINEAPPLE) is an observational, multi-
national observational clinical trial to explore the route from 
the first sign of abdominal pain to the diagnosis of pancre-
 Key Words 
 Pediatric pancreatitis · Acute pancreatitis · Abdominal pain · 
Pancreatic enzyme · Evidence-based medicine 
 Abstract 
 Background: There are unexpectedly large differences be-
tween the incidences of acute pancreatitis (AP) as indicated 
by different hospitals. Retrospective studies suggest that the 
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What Is Known
 • AP is an underdiagnosed disease in children. 
 • No evidence-based guidelines are available to give proper instruction concerning the necessity of pan-
creatic enzyme measurement during abdominal pain. 
 • No large worldwide prospective clinical trials exist for understanding the most common clinical char-
acteristics of AP. 
What Is New
 • A multinational prospective clinical trial is registered and open for all centers. 
 • This is the first large worldwide study to explore the route from the first sign of abdominal pain to the 
diagnosis of AP (PINEAPPLE-P). 
 • This trial will help to diagnose AP in a reliable and cost-efficient way. 
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atitis (PINEAPPLE trial). The PINEAPPLE-R subtrial is a retro-
spective review on the records of children (patients under 
18) appearing at emergency units – a review of their clinical 
symptoms, results of imaging examinations and laboratory 
parameters. The PINEAPPLE-P subtrial is a prospective trial 
designed to develop a fast and simple EBM guideline that 
helps to evaluate (in a reliable and cost-efficient way) the 
necessity of pancreatic enzyme test and abdominal ultraso-
nography (or even computed tomography) when a child has 
abdominal pain. The trial has been registered at the ISRCTN 
registry and has received the relevant ethical approval.  Key 
Message: The PINEAPPLE trial will help to recognize AP in 
children in a highly efficient manner.  © 2015 S. Karger AG, Basel 
 Introduction 
 Several publications describe an increasing incidence 
of acute pancreatitis (AP) in both children and adults  [1–
3] . Importantly, AP became the most common reason of 
hospitalization in the United States in 2012 with over 
270,000 discharges  [4] . The reason behind the impressive 
incidence of AP could be either improved awareness of 
the disease and/or the elevated number of the new inci-
dence  [5–7] .
 Although two major studies have proved that the inci-
dence of AP is not much less in children than in adults 
(3.6–13.2 per 100,000), the overall incidence is below 
1 per 100,000 or even less worldwide  [8, 9] . A retrospec-
tive trial in Pittsburgh suggested a close relationship be-
tween the number of serum amylase and lipase measure-
ment and the rising incidence of the disease  [7] . Their 
data showed that the increased pancreatic enzyme testing 
could account for 94% of the change in all AP admission, 
suggesting that pediatric pancreatitis is an underdiag-
nosed disease.
 There are factors that make the diagnosis of AP chal-
lenging when it comes to ordering pancreatic enzymes: 
(i) abdominal pain is a common complaint in kids; 50% 
of the cases are in the category of pain-predominant func-
tional gastrointestinal disorder with no significant mor-
bidity  [10] , (ii) most of the hospitals cannot afford mea-
suring serum amylase/lipase in every children having ab-
dominal pain  [10] , however (iii) no evidence-based 
medicine (EBM) guidelines are available to give proper 
instruction concerning the necessity of pancreatic en-
zyme measurement during abdominal pain. Therefore, 
most of the pancreatic enzyme test ordering are based on 
individual experience of the clinicians. It is almost need-
less to say that international clinical observational trials 
are crucially needed to understand the most common 
clinical characteristics of AP.
 The Hungarian Pancreatic Study Group (HPSG) was 
established in 2011 in order to improve patients’ life 
 suffering in pancreatic diseases. To achieve our aims, we 
(i) developed an electronic data registry and biobank 
for patients (www.pancreas.hu), (ii) published the cur-
rently available EBM guidelines  [11–15] , (iii) estab-
lished specific study sessions including a pediatric ses-
sion, and (iv) organized multicentre clinical trials  [16, 
17]. 
 Here we propose a multicenter, clinical trial called 
PINEAPPLE (Pain in Early Phase of Pediatric Pancreati-
tis), which is open to all institutions to join in. The trial 
protocol aims at exploring the route from the first sign of 
abdominal pain to the diagnosis of pancreatitis in a retro-
spective (PINEAPPLE-R) and prospective (PINEAPPLE-
P) way.
 Methods 
 Preliminary Settings 
 The study has been initiated and drafted by the HPSG. The 
protocols have been introduced in our latest international meet-
ing held in Szeged in November 2014 (http://pancreas.hu/sites/
info/files/conferences/ALPD2014-Program.pdf), which was at-
tended by some of the well-established pediatric pancreatologists. 
Around 100 clinicians – 60 Hungarians and 40 international 
(from 9 different countries) investigators attended. The trial has 
been discussed and the suggested modifications have been includ-
ed. The study has been discussed and accepted by the scientific 
committee of the International Association of Pancreatology 
(IAP), and therefore, it is running under the auspices of HPSG and 
IAP.
 Ethical Issues 
 The studies have received the relevant ethical approval (No.: 
ad.52857-2/2014) issued by the National Hungarian Ethical Au-
thority (ETT TUKEB). Study management will strictly follow the 
Ethical Guidelines for Observational Studies.
 Trial Registration 
 The PINEAPPLE trial has been registered at the ISRCTN reg-
istry (ISRCTN35618458), which is a primary clinical trial registry 
recognized by WHO and ICMJE, which accepts all clinical re-
search studies, providing content validation and curation and the 
unique identification number necessary for publication.
 Centers throughout the world are welcome to participate in the 
PINEAPPLE trial. ‘Online Call for Centers’ will be available at 
http://www.pancreas.hu/en/studies/pineapple. Completion of the 
‘LETTER OF INTENT’ form will be mandatory for registering 
participation of each institution. HPSG will acknowledge receipt 
of the ’LETTER OF INTENT’ form and will contact centers pro-
viding them with additional study information.
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 Patients and Centers Involved in the Trial 
 The PINEAPPLE trial is divided into 2 subtrials.
 The aim of PINEAPPLE-R is a retrospective review on records 
of children (patients under 18) appearing at emergency units in 
one or two months depending on the size of the center; the review 
is centered around their clinical symptoms, results of imaging ex-
aminations and laboratory parameters.
 The aim of PINEAPPLE-P is to provide a fast, simple and au-
thentic system that helps to evaluate (in a reliable and cost-efficient 
way) the necessity of pancreatic enzyme test and abdominal ultra-
sonography (or even computed tomography) when a child has ab-
dominal pain.
 For the PINEAPPLE-R subtrial, we aim to collect around 
1,000–2,000 cases (appearing in the ER unit with any kind of rea-
sons/symptoms) from each center. Preliminary data suggested 
that around 5–10% of children admitted to the ER unit have ab-
dominal pain. Therefore, per center, we expect around 100–200 
cases with abdominal pain. Altogether, we wish to collect around 
20,000 cases with abdominal pain within 3 years.
 The PINEAPPLE-P is for patients under 18 years old appearing 
at ER unit with a leading symptom of abdominal pain. Our aim 
was to collect around 100 cases from each center. Altogether we 
wish to collect around 20,000 cases with abdominal pain within 
3 years (http://www.pancreas.hu/en/studies/pineapple).
 Protocol for Retrospective Data Collection for PINEAPPLE-R 
 This is a pure retrospective review of electronic computerized 
records of the relevant centers. Diagnosis and data concerning ba-
sic clinical symptoms (abdominal pain [yes/no], vomiting [yes/
no], nausea [yes/no]) are required for all patients appearing on the 
ER unit. A diagnosis of abdominal pain is decided based on the 
doctor’s opinion/record. If the patient has abdominal pain, infor-
mation about the imaging examination of the pancreas (yes/no, if 
yes: positive/negative for pancreatitis) and laboratory parameters 
pancreatic enzyme measurements (either amylase or lipase, yes/
no, if yes whether it is increased with 3×) are obligatory. Where 
data are available, information concerning the experience of the 
doctor in charge needs to be given (experienced doctor: at least 10 
years experience with board certification, beginner: others). The 
information is collected into a uniform harmonized excel sheet 
that can be downloaded from the study website (http://pancreas.
hu/en/studies/pineapple).
 Inclusion Criteria for PINEAPPLE-R 
 • Under 18 years old 
 • Accurate electronic data mentioned in the protocol 
 Exclusion Criteria for PINEAPPLE-R 
 • Above 18 years old 
 • Inaccurate electronic data mentioned in the protocol 
 Protocol for Prospective Data Collection for PINEAPPLE-P 
 The PINEAPPLE-P subtrial has a questionnaire style data-col-
lection method. The form is available on the web system http://
www.pancreas.hu/en/studies/pineapple ( table  1 ). The patients 
and parents have to be informed accordingly. The ‘informed con-
sent form’ needs to be signed and the ‘Questionnaire’ needs to be 
filled out. Four quality control points are established. First, the 
local clinical research assistant must upload the data electroni-
cally and confirm that the data are the same as those in the hard 
copy. Second, the local institutional principal investigator (who 
has to have a medical doctoral degree) must recheck the uploaded 
data and confirm their validity and accuracy. Third, the central 
data administrator, who is based at the headquarters of HPSG, 
must control the accuracy and finally, the trial leader must go 
through the details. Patients with inadequate or insufficient data 
will be excluded.
 Inclusion Criteria for PINEAPPLE-P 
 • Under 18 years old 
 • The leading symptom is acute abdominal pain 
 Exclusion Criteria for PINEAPPLE-P 
 • Above 18 years old 
 • No or chronic abdominal pain 
 Statistical Analyses 
 Patients data will be analyzed in 4 different age categories (0–
6, 6–10, 10–16, 16–18 years). Association between each collected 
parameters (medical history, symptoms, etc.) and AP will be de-
termined. Statistical analysis will be carried out by data mining 
methods. The applied methods will be determined based on the 
main characteristics of the collected data, and the most suitable 
method – or method combination – will be chosen. The following 
data mining methods are being contemplated: logistic regression, 
discriminant analysis, random forest analysis, decision tree, clus-
ter analysis. ROC analysis and/or confusion matrix will be per-
formed to evaluate the predictive power of the classification al-
gorithm.
 Expected Results 
 PINEAPPLE-R study will help to understand our current clin-
ical practice on patients with abdominal pain in different countries 
and centers. The PINEAPPLE-P study will help to establish an 
EBM guideline, which will help to provide a fast, simple and au-
thentic system to evaluate (in a reliable and cost-efficient way) the 
necessity of the pancreatic enzyme test and abdominal ultrasonog-
raphy when a child has abdominal pain.
 Authorship Policy 
 In order to give appropriate credit to each investigator/cen-
ter, we will use standardized authorship policy. Concerning the 
PINEAPPLE-R subtrial: under 1,500 patients will generate 
1, whereas above 1,500 patients will generate maximum of 2 co-
authors from the center PINEAPPLE-P: every 100 patients will 
generate 1 co-author. All other investigators/contributors who do 
not meet the criteria for authorship will be listed in an ‘Acknowl-
edgements’ section. For example, those who provide purely techni-
cal help or a department chair who provided only general support 
will appear in this section.
 Discussion 
 The 2 out of 3 criteria rule is used to dianose AP both 
in adults and children  [9, 11, 13] . Two of the following 
parameters are required: (1) abdominal pain, (2) serum 
amylase and/or lipase values  ≥ 3 times upper limits of 
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Table 1.  Summary of clinical data required for PINEAPPLE-P
1. Patient personal details
Gender Male/female
Ethnicity/race White/Black/Asian-Indian/not known
2. Details from the medical history  
(a) Family medical history  
Pancreas disorders in family history: AP/CP/AIP/PC Yes/no, if yes: relationship to patient
(b) Medical history of the child  
Known diseases Yes/no, if yes: description of the disease
Abdominal surgery Yes/no, if yes: description of the disease
New medications taken in the last 2 weeks Yes/no, if yes: description of them
New symptoms in the last 2 weeks Yes/no, if yes: description of them
New diet, change in diet in the last 2 weeks Yes/no, if yes: description of it
Any event strongly affecting the child emotionally in the last 2 weeks Yes/no, if yes: description of it
Any event strongly affecting the child emotionally in the last 2 weeks Yes/no, if yes: description of it
Change in the environment of the child in the last 2 weeks Yes/no, if yes: description of it
Was there any examination concerning abdominal pain? Yes/no, if yes: description of it
Length of breast milk feeding Number of months
3. Complaints, symptoms  
(a) Abdominal pain  
How many hours have passed since the pain started? Number of hours
How long did it last? Number of hours
Intensity on a 1–10 scale Number
Intensity Decreasing/intensifying/stagnating
Forced posture Yes/no
Nature Dull/sharp/cramping
Location Diffuse/localized
(b) In case of abdominal pain longer than 48 h
Was the everyday activity influenced? Yes/no
Did the child wake up at night because of the pain? Yes/no
Which part of the day the pain appeared mostly? After waking up/in the morning/in the Afternoon/in the 
evening/at night
Was it connected to eating? Yes/no
Subfebrility, fever Before eating/while eating/after eating
(c) Other complains  
Nausea Yes/no
Vomiting Yes/no, if yes: how many times?, and content of cast
Subfebrility, fever Yes/no, if yes: since when? Temperature
Appetite Good/retained/bad
Weight loss Yes/no, if yes: how much? (kg), how long did it take? (weeks)
Jaundice Yes/no, if yes: since when?
Stool Normal/diarrhea/constipation/fatty/putrid/undigested food/
bloody/mucus
4. Admission details, status  
Blood pressure, mm Hg, heart rate, /min Number
Body weight, kg, body height, m Number
Respiratory rate, /min Number
Body temperature, °C Number
Abdominal tenderness Yes/no, location of abdominal tenderness
Abdominal guarding Yes/no
Jaundice Yes/no
Bowel sounds No/hypoactive/normal/hyperactive
5. Laboratory parameters  
Amylase and/or lipase, U/l  
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normal, (3) characteristic imaging finding for AP. There-
fore, without measuring serum pancreatic enzymes and/
or performing either transabdominal ultrasonograpy or 
CT, AP cannot be diagnosed. According to previous pe-
diatric studies in AP, abdominal pain is present in 66 to 
95% of the children with AP  [18–24] ; however, inconsis-
tency and high variability exist between the studies. Most 
of the trials investigating the characteristics of abdominal 
pain have either low numbers or missing parameters 
causing inconsistencies between their data. Abdominal 
pain was most commonly localized to the epigastric re-
gion (62–89% of cases)  [18, 25, 26] and was rarely associ-
ated with back pain (<10%)  [20, 24] . Radiation to the 
back was only in 1.6–5.6%  [22, 23, 26] of the cases. Dif-
fuse abdominal pain was reported in 12–20% of patients 
 [18, 22, 23] , guarding at 29–37%  [18, 20] , whereas nausea 
or vomiting was found in 40–80% of patients  [21–29] . A 
clinical study from Mexico described ileus at just under 
50% of the children  [27] . Abdominal distension was re-
ported in 21–46% of the patients  [18–22] . Other symp-
toms might be fever, ascites, pleural effusion and jaun-
dice. Palpable abdominal mass was reported in a quarter 
of the patients in a study from Taiwan  [26] . Symptoms 
of infants and toddlers are much more unspecific: fever 
with abdominal pain is found in 43%, epigastric tender-
ness in 57%, nausea in 29%  [25] . In a study from Pitts-
burgh, 16% of the infants and toddlers had abdominal 
distension and 40% had fever  [30] . Therefore, it is almost 
needless to say that a large international prospective co-
hort is necessary to understand the complaints and 
symptoms of AP in children.
 In summary, here we propose an international obser-
vational clinical trial (PINEAPPLE) to collect a critical 
mass of clinical data from children with abdominal pain 
in order to develop EBM guidelines concerning the ne-
cessity for obtaining serum pancreatic enzyme testing 
and pancreatic imaging in pediatric patients who present 
to the emergency room with abdominal pain.
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6. Imaging examinations at admission  
Pancreas deviation suggesting AP Yes/no
Pancreas deviation suggesting CP Yes/no
7. Diagnosis  
8. Diagnosis – main group Unknown, autoimmun, cardiology, dermatology, 
endocrinology, gastroenterology, etc.
9. What happened with the patient? Admission to an inpatient department/went home/other
Table 1. (continued)
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